

Saturday, December 3, 2016

09:00 - 18:00: Workshop (WS01): IASLC Supporting the Implementation of Global CT Screening
(Ticketed Session: €100,00)

Track: Radiology/Staging/Screening
Room: Strauss 1

Organization Committee:

Chairs: John Field, UK & James L Mulshine, USA
Matthijs Oudkerk, The Netherlands
David Yankelevitz, USA
Annette McWilliams, Australia
Heidi Schmidt, Canada
Hisao Asamura, Japan
Javier Zulueta, Spain
Robert Smith, USA
Nir Peled, Israel

Objectives:

1. This IASLC SSAC Workshop will provide an overview of the recent advances in lung cancer screening.
2. To provide a forum to discuss the pertinent issues around implementation, which will impact on all health services as they move towards implementation.
3. What can be achieved in the next three years and recommendation for the IASLC Exec as to how they can support leadership in this area of lung cancer.
4. The consensus from this workshop will be published.

Program:

09.00 - Welcome and Aims of Workshop - John K. Field, UK

Session 1: 09.10 - 09.50

Integrating Smoking Cessation into Future Lung Cancer CT Screening Programs - Utilizing the 'Teachable Moment'

Chairs: Avi Spira, USA & Robert Smith, USA

- 09.10 - Personalize Tobacco Cessation in the CT Screening Setting
Jamie Ostroff, USA
- 09.25 - Opportunities to Enhance the Cost Effectiveness of CT Screening through the Integration of Tobacco Cessation
Bill Evans, Canada
- 09.40 - Discussion

Session 2: 09.50 - 11.00

Radiological Imaging and Work-Up

Chairs: Heidi Schmidt, Canada, Arnie Devaraj, UK, Pierre Massion, USA & Nir Peled, Israel

- 09.50 - CT Scan Detected Nodule Management Protocol
Matthijs Oudkerk, The Netherlands

- 10.05 - **Innovative Approaches to Quantitative Imaging Quality Control for Lung Cancer Screening**
Ricardo Avila, USA
- 10.20 - **Opportunities to Advance Lung Cancer Screening Approaches Using Data Registries**
David Yankelevitz, USA
- 10.35 - **Progress in Advancing Lung Cancer Screening Internationally**
John K Field, UK
- 10.50 - **Discussion**
- 11.00 - **Coffee Break**

Session 3: 11.30 - 12.30

Integration of Molecular Biomarkers and Utilization of CT for CHD & COPD

Chairs: Gabriella Sozzi, Italy, Javier Zulueta, Spain & Claudia Henschke, USA

- 11.30 - **The Power of Micro Simulation Modelling in Lung Cancer Screening**
Kevin Ten Haaf, The Netherlands
- 11.45 - **ImaLife**
Rozemarijn Vliegenthart, The Netherlands
- 12.00 - **Lung CT Screening: Complementary Benefits - CHD & COPD**
Claudia Henschke, USA
- 12.15 - **Discussion**
- 12.30 - **Lunch**

Session 4: 13.30 - 15.50

**The Current Global Implementation of CT Lung Cancer Screening Programs Outside the USA
(Please note 10 minutes per presentation)**

Chairs: Matthijs Oudkerk, The Netherlands, Kwun Fong, Australia, David Baldwin, UK, Shun-ichi Watanabe, Japan, Robert Smith, USA

- 13.30 - **The Shanghai Screening Trial**
Liu Shi-Yuan, China
- 13.50 - **Update on Low-dose CT Lung Cancer Screening Implementation in USA**
James Mulshine, USA
- 14.00 - **The Current Implementation Plan in Canada**
Stephen Lam, Canada
- 14.10 - **Surgical Status of Screen Detected Lung Cancer - Future Prospective?**
Shun-ichi Watanabe, Japan
- 14.20 - **Lung Cancer Screening in Australia**
Kwun Fong, Australia
- 14.30 - **Developing Lung Cancer Screening Plans in South America**
Ricardo Terra, Brazil
- 14.40 - **Annual or Biennial Lung Cancer Screening - What Is the Evidence?**
David Yankelevitz, USA
- 14.50 - **Netherlands & Europe Awaiting the NELSON Publication Prior to Implementation**
Harry De Koning, The Netherlands
- 15.00 - **US National Lung Cancer Round Table**
Robert Smith, USA
- 15.10 - **Discussion**

- 15.50 - Tea Break

Session 5: 16.20 - 17.30 (Round Table Discussion)

What can be achieved in the next three years and recommendation for the IASLC Exec as to how they can support leadership in this area of lung cancer.

Chairs: John K Field, UK & Jim Mulshine, USA

Each Question will be addressed for 3 minutes by the Lead Discussant and then opened up for general discussion.

Questions to be addressed:

1. **Identification of the hard to reach community for lung cancer screening - how?**
Discussant: David Baldwin, UK
2. **Use of quantitative imaging in the screening setting - do we need accreditation?**
Discussant: Matthijs Oudkerk, The Netherlands
3. **CT screen detected registries - what are the possibilities for international co-operation?**
Discussant: David Yankelevitz, USA
4. **How do we develop international recommendation for the work-up of CT screen detected nodules?**
Discussant: Ricardo Avila, USA
5. **How can IASLC Exec support leadership in lung cancer CT screening?**
Discussants: John K Field, UK & Jim Mulshine, USA

18.00: Networking Dinner

**The CT Screening Workshop Registration cost includes: Buffet, Lunch & Dinner
CPD Accredited Workshop (6 points)**

08:00 - 17:00: Workshop (WS02): Young Investigator Research and Communication Training (Sign up Required)

Track: Trial Design/Statistics

Room: Schubert 1 & 2

Moderator: Lloyd Bracey, UK

The 2016 WCLC Local Organizing Committee is organizing a young investigator communications workshop prior to the 2016 WCLC Conference. The workshop will address how to structure and deliver effective presentations on clinical research, and how to deal with resulting questions effectively. The workshop will comprise two teaching lectures by a lead coach. These will be entertaining and will simultaneously teach and illustrate the principles under discussion. After each lecture participants will break into groups to engage in interactive practical exercises. Every delegate will be expected to participate, including giving a presentation. Applications of interested delegates will include a CV as well as two recommendation letters and will be reviewed by the Local Organizing Committee for final approval and selection. To view the application process, please click [here](#).

Sunday, December 4, 2016

08:00 - 11:45: (JCES01) Joint IASLC - Chinese Society for Clinical Oncology - Chinese Alliance Against Lung Cancer Session (Sign up Required)

Room: Stolz 1

Chairs: Fred R. Hirsch, USA & Yi Long Wu, China, ChunXue Bai, China

- 08:00 - **Breakfast and Informal Networking**
- 08:20 - **Welcome and Introduction**
Fred R. Hirsch, USA & Yi Long Wu, China, ChunXue Bai, China

Discovering the East: Precision Medicine in China

- 08:30 - **JCES01.03: Perspectives on Precision Medicine for Early Stage NSCLC**
Jie Hu, China
- 08:50 - **JCES01.04: Liquid Biopsy in Monitoring Dynamic Changes of Driver Genes in Advanced NSCLC**
Qing Zhou, China
- 09:10 - **JCES01.05: New Clinical Trials on Gene Alteration in China**
Shun Lu, China

Precision Medicine - Perspectives from the West

- 09:30 - **JCES01.06: European Perspective Phase I Strategy**
Christian Diego Rolfo, Belgium
- 09:50 - **JCES01.07: North American Perspective**
Fred R. Hirsch, USA

Break - 10:10 - 10:30

Abstract Presentations from China Related to Precision Medicine

- 10:30 - **JCES01.09: A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR-TKI Resistance**
Wenxian Wang, China
- 10:40 - **JCES01.10: Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer**
Zhengbo Song, China
- 10:50 - **JCES01.11: Altered Expression of Programmed Death-Ligand 1 after Neo-Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma**
Yue Zhao, China
- 11:00 - **Discussant Oral Abstracts**
James Chih-Hsin Yang, Taiwan
- 11:15 - **Discussant Posters**
Xu-Chao Zhang, China
 - **JCES01.14: Mutational Profiling of Non-Small-Cell Lung Cancer Patients Resistant to First-Generation EGFR Tyrosine Kinase Inhibitors Using next Generation Sequencing** - Ying Jin, China
 - **JCES01.15: Analysis of Genomic Alterations and Heterogeneity in Pulmonary Adenoid Cystic Carcinoma by Next-Generation Sequencing** - Min Li, China

- JCES01.16: A MET Inhibitor in the Treatment of Metastatic Non Small Cell Lung Cancer with MET Amplification - Junling Li, China
- JCES01.17: A Phase I Dose Expansion Study of Epirubicin to Evaluate Efficacy and Safety in EGFR Mutation Positive (EGFRm+) NSCLC Patients with Brain Metastasis - Qing Zhou, China
- JCES01.18: Dual Positive PD-L1 and CD8+ TIL Represents a Predominant Subtype in NSCLC and Correlates with Augmented Immunogenicity - Si-Yang Liu, China
- JCES01.19: Clinicopathologic Characteristics, Genetic Variability and Therapeutic Options of RET Rearrangement Patients in Lung Adenocarcinoma - Zhengbo Song, China
- JCES01.20: Patients with ROS1 Rearrangement Positive Non-Small Cell Lung Cancer Benefit from Pemetrexed-Based Chemotherapy - Zhengbo Song, China
- JCES01.21: Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection - Zhengbo Song, China
- JCES01.22: Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Patients with Non-Small Cell Lung Carcinoma - Ting Xu, China
- JCES01.23: EGFR Mutation Status Analysis in Cerebrospinal Fluid and Plasma of Advanced Lung Adenocarcinoma with Brain Metastases - Zhe Liu, China
- JCES01.24: Molecular Mechanism of Transformation from Adenocarcinoma to Small-Cell Lung Cancer after EGFR-TK - Jiefei Han, China
- 11:30 - Closing Remarks

08:00 - 11:45: Workshop (WS03): IASLC Meets ESTI: Imaging in Lung Cancer Staging and Diagnosis

Track: Radiology/Staging/Screening

Room: Strauss 2

Chairs: Helmut Prosch, Austria & Ramon Rami-Porta, Spain

- **T Stage**
Helmut Prosch, Austria
- **N Stage**
Cornelia Schäfer-Prokop, The Netherlands
- **M Stage**
Nicola Sverzellati, Italy
- **Ultrasound- and CT-Guided Biopsies for the Diagnosis of Lung Cancer**
Gerhard Mostbeck, Austria

08:00 - 11:45: Young Investigator Session (YI01a): Clinical Trials & Scientific Mentoring

Clinical Trials: Design, Publication & Interpretation

Room: C8

Chairs: Luigi De Petris, Sweden & TBD

- 08:00 - How to Implement an Idea/Hypothesis into a Clinical Trial
Carlos Silva, Argentina
- 08:20 - Basic Statistical Considerations
Lothar Pilz, Germany
- 08:40 - How to Effectively Publish your Results: Suggestions from the JTO Editor
Alex Adjei, USA
- 09:00 - Critical Eye on Practice Changing Literature
Jin Soo Lee, South Korea

09:30 - **Coffee Break**

09:45 - **Young Investigator Session (YI01b): Scientific mentoring**

Chairs: Amanda Tufman, Germany & Alex Adjei, USA

- 09:45 - **Important Factors for a Professional Career**
Martin Edelman, USA
- 10:05 - **Expectations from a Young Investigator**
Matthias Scheffler, Germany
- 10:20 - **Scientific Mentoring: The Reality**
Mirjana Rajer, Slovenia
- 10:35 - **Scientific Mentoring in China**
Zhijie Wang, China
- 10:50 - **Meeting with Scientists**
Alex Adjei, USA, Martin Edelman, USA, James Jett, USA, Jin Soo Lee, South Korea,
Carlos Silva, Argentina & Zhijie Wang, China

08:00 - 11:00: Mesothelioma Workshop (WS04) (Ticketed Session: €25,00)

Room: Schubert 2

Chair: Michele Carbone, USA

- 08:00 - **Debate - Extrapleural Pneumonectomies Should NOT be Performed for Pleural Mesothelioma**
David Jablons, USA, Raja Flores, USA & Isabelle Schmitt-Opitz, Switzerland
- 08:50 - **Q&A**
- 09:00 - **Debate - Immunotherapy Does NOT Work in Mesothelioma**
Hedy Kindler, USA, Luciano Mutti, UK, Paul Bass, The Netherlands & Daniel Sterman, USA
- 09:50 - **Q&A**
- 10:00 - **Debate - Induction Chemotherapy is Better than Postoperative Adjuvant Therapy for Early Stage Pleural Mesothelioma**
Anne Tsao, USA, Walter Weder, Switzerland, Marc de Perrot, Canada, Wickii Vigneswaran, USA
- 10:50 - **Q&A**

08:00 - 12:00: (WS05): International Society of Nurses in Cancer Care (ISNCC) & BMS Foundation Collaborative Workshop (Sign up Required)

Track: Nurses

Room: Schubert 4

- **How to Develop a Comprehensive System of Care for Lung Cancer Patients**
Bristol-Myers Squibb

08:00 - 13:00: Management of Lung Cancer Patients Through Innovative Laboratory Testing Across the Clinical Continuum Workshop (Sign up Required)

Chair: Felix Herth, Germany

Room: TBD

- 08:00 - **Introduction**
Felix Herth, Germany
- 08:15 - **Serum-based Protein Tumor Markers**
Rafael Molina, Spain

- 09:00 - Lung Panel IHC, PD-L1, ALK, ROS1, EGFR
Fernando Lopez-Rios, Spain
- 09:55 - EGFR Plasma
David Gonzalez de Castro, UK
- 10:40 - Sequencing Data
Max Diehn, USA
- 11:25 - Summary
Felix Herth, Germany
- 11:40 - Panel Discussion
Keith Miller, USA, Rafael Molina, Spain, Fernando Lopez-Rios, Spain, David Gonzalez de Castro, UK, Max Diehn, USA & Felix Herth, Germany
- 12:15 - Coffee and Pastries at Opening and Box Lunches Offered at End of Session

10:30: Press Conference (PR01)

Room: Schubert 1

12:00 - 13:30: Industry Supported Symposium: ISS Current and Emerging Treatments for Patients with ALK+ NSCLC - ARIAD Pharmaceuticals Inc.

Room: Strauss 3

Chairs: Christoph Zielinski, Austria & Ross Camidge, USA

- 12:00 - **Welcome & Introduction**
Christoph Zielinski, Austria & Ross Camidge, USA
- 12:05 - **ALK inhibitors: Current Treatments and Sequencing**
Christoph Zielinski, Austria
- 12:30 - **The Future of ALK Inhibitors: How the Treatment Paradigm May Change**
Ross Camidge, USA
- 12:55 - **Will Mutation Testing be Standard in the Resistant Setting?**
Pasi A. Jänne, USA
- 13:20 - **Summary and Conclusions**
Christoph Zielinski, Austria & Ross Camidge, USA

13:45 - 15:15: Industry Supported Symposium: ISS ALK and ROS1 in NSCLC: Optimising the Continuum of Care- Pfizer Oncology

Room: Lehar 3-4

Chair: Benjamin Solomon, Australia

- 13:45 - **Welcome & Introduction**
Benjamin Solomon, Australia
- 13:50 - **The Importance of Molecular Testing in NSCLC**
Benjamin Solomon, Australia
- 14:00 - **ALK+ NSCLC: How can we Maximise Clinical Outcome Today?**
Nicolas Girard, France
- 14:20 - **Clinical Consequences of Resistance to ALK Inhibitors**
Christine Lovly, USA
- 14:40 - **Panel Discussion**
All Faculty
- 14:50 - **ROS1+ NSCLC: Clinical Data and Experience**
Benjamin Solomon, Australia
- 15:05 - **Panel Discussion**

All Faculty

- 15:10 - **Meeting Close**
Benjamin Solomon, Australia

13:30 - 18:30: International Thoracic Oncology Nursing Forum (ITONF) and Mesothelioma Satellite Workshop: *Innovating Lung Cancer and Mesothelioma Care* (WS07) (Ticketed Session: €25,00)

Track: Nurses

Room: Schubert 2

Chair: John McPhelim, UK

Globalization of Nursing in Lung Cancer and Mesothelioma Care

- 13.30 - **Opening - Welcome**
Maria Guerin, UK
- 13.35 - **Leveraging Technology and Social Media in Nursing**
Anne Ireland, USA
- 14:00 - **E-health and Future Technologies in Evidence Based Nursing Care**
Roma Maguire, UK
- 14:20 - **Nursing Management in Japan**
Sarah Nagamatsu, Japan
- 14:35 - **Q&A**
Panel Discussion

Immunotherapy - The New Kid on the Block

- 14:40 - **Immunotherapy Challenges in Lung Cancer & Mesothelioma**
Sanjay Popat, UK
- 15:05 - **Nursing Opportunities & Challenges for Immunotherapy**
Beth Eaby-Sandy, USA
- 15:20 - **Nurse Led Follow up Clinics - Effective in Immunotherapy?**
Mary Duffy, Australia
- 15:35 - **Q&A**
- 15:40 - **Break**

Clinical Trials - Supporting Trials and Our Patients

Chair: Mary Duffy, Australia

- 16.00 - **Clinical Trial Participation - The Nurses Role**
Massey Nematollahi, Canada
- 16:15 - **Lung Cancer Nurse Attitudes to Clinical Research in the UK**
John McPhelim, UK
- 16:30 - **Considerations for Surgical Clinical Trials**
Melissa Culligan, USA
- 16:45 - **Q&A**
Panel Discussion

Changing Face of Lung Cancer

Chair: Mary Duffy, Australia

- 16:50 - **Frailty Assessment Prior to Treatment Initiation**
Patsy Yates, Australia

- 17:10 - **A Glimpse into Lung Cancer Nursing in Denmark**
Marianne Cumberland, Denmark
- 17:25 - **New Lung Cancer Patient Resource**
Silvia Novello, Italy
- 17:35 - **Q&A**

Smoking Cessation in Lung Cancer and Mesothelioma Patients

Chair: Mary Duffy, Australia

- 17:40 - **Vapping - A Good Smoking Cessation Tool?**
Sanjay Agrawal, UK
- 17:55 - **Smoking Cessation - It's the Nurses Role?**
Caitlin Broderick, Australia
- 18:10 - **Q&A**
- 18:25 - **Close**
Melissa Culligan, USA

15:30 - 17:00: Industry Supported Symposium: ISS Non-Small Cell Lung Cancer: The Programmed Death-Ligand 1 (PD-L1) Receptor as a Target for Monotherapy and in Combination - Merck-Pfizer Alliance

Room: Hall C2

Chair: Sanjay Popat, UK

- 15:30 - **Welcome and Overview**
Sanjay Popat, UK
- 15:45 - **Anti-PD-L1 Monotherapy in NSCLC: Overview of the Trials Examining PD-L1 Monotherapy in NSCLC**
Rosalyn Juergens, Canada
- 16:00 - **Anti-PD-L1 Combined with Other Agents in NSCLC: Established and Novel Targeted Agents**
Jhanelle Gray, USA
- 16:15 - **Anti-PD-L1 Combined with Other Agents in NSCLC: IO-IO Combinations**
Sacha Rothschild, Switzerland
- 16:30 - **Anti-PD-L1 Agents: Opportunities for Differentiation**
Hossein Borghaei, USA
- 16:45 - **Summary, Questions and Close**
Sanjay Popat, UK

17:15 - 18:45: Industry Supported Symposium: ISS Treatment Selection Strategies in Advanced NSCLC - A Symphony of Views - Eli Lilly and Company

Room: Hall C1

Chairs: Giorgio Scagliotti, Italy & Tony Mok, Hong Kong

- 17:15 - **Welcome & Introduction**
Giorgio Scagliotti, Italy & Tony Mok, Hong Kong
- 17:20 - **Orchestral Manoeuvres of the Immuno Checkpoints: Targeted or Untargeted Agents?**
Joachim Aerts, The Netherlands
- 17:45 - **Variation on a Theme: Angiogenesis Inhibition Across Treatment Lines**
Maurice Pérol, France
- 18:05 - **Fine Tuning Bio Marker Driven Choices in 2nd Line**

Luis Paz-Ares, Spain

- 18:25 - **Is the Score Yet Written?**
Giorgio Scagliotti, Italy
- 18:30 - **Discussion: the Unfinished Symphony**
Tony Mok, Hong Kong

19:00 - 20:45: Opening Plenary Session (PL01)

Room: Hall D (Plenary Hall)

- **PI01.01: Keynote Lecture: Is Smoking a Sole Factor in Lung Cancer Development?**
Harald zur Hausen, Nobel Laureate, Germany

20:45 - 21:45: Welcome Reception

Room: Hall B (Exhibit Hall)

Monday, December 5, 2016

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH01)

Tracks: 01. Epidemiology/Tobacco Control and Cessation/Prevention
02. Biology/Pathology

Room: Hall C1

Chairs: Martin Filipits, Austria & Tetsuya Mitsudomi, Japan

- **Prevention**
Carolyn Dresler, USA
- **Biology**
Roman Thomas, Germany
- **Pathology**
Keith Kerr, UK

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH02)

Tracks: 08. SCLC/Neuroendocrine Tumors
09. Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

Room: Hall C7

Chairs: Raffit Hassan, USA & Georg Pall, Germany

- **SCLC**
Joan Schiller, USA
- **Malignant Pleural Mesothelioma**
Anna Nowak, Australia
- **Thymic Malignancies & Esophageal Cancer**
Peter Hohenberger, Germany

07:30 - 08:30: Meet the Expert (MTE01) (Ticketed Session: €35,00)

Track: Epidemiology/Tobacco Control and Cessation/Prevention

Room: Schubert 1

- **Strategies to Improve Tobacco Control in Central European Countries**
Manfred Neuberger, Austria & Martina Pötschke-Langer, Germany

07:30 - 08:30: Meet the Expert (MTE02) (Ticketed Session: €35,00)

Track: Biology/Pathology

Room: Schubert 2

- **Advances in Pathology**
Lukas Bubendorf, Switzerland

07:30 - 08:30: Meet the Expert (MTE03) (Ticketed Session: €35,00)

Track: Biology/Pathology

Room: Schubert 4

- **Basics of Molecular Biology for the Clinician**
Antonio Marchetti, Italy

07:30 - 08:30: Meet the Expert (MTE04) (Ticketed Session: €35,00)

Track: Radiology/Staging/Screening

Room: Schubert 5

- **Screening for Lung Cancer**
Christine Berg, USA & Nir Peled, Israel

07:30 - 08:30: Meet the Expert (MTE05) (Ticketed Session: €35,00)

Track: Surgery | Radiotherapy | Locally Advanced NSCLC

Room: Schubert 6

- **Where is the Place of Surgery for N2 Disease?**
Corinne Faivre-Finn, UK & Paul Van Schil, Belgium

07:30 - 08:30: Meet the Expert (MTE06) (Ticketed Session: €35,00)

Track: Radiotherapy

Room: Strauss 3

- **Radiotherapy Techniques in Lung Cancer**
Ritsuko Komaki, USA & Martin Stuschke, Germany

07:30 - 08:30: Meet the Expert (MTE07) (Ticketed Session: €35,00)

Track: Chemotherapy/Targeted Therapy/Immunotherapy | Advanced NSCLC

Room: Lehar 1-2

- **Treatment of Elderly Patients with Lung Cancer**
Cesare Gridelli, Italy & Corey Langer, USA

07:30 - 08:30: Meet the Expert (MTE08) (Ticketed Session: €35,00)

Track: Chemotherapy/Targeted Therapy/Immunotherapy | Early Stage NSCLC | Locally Advanced NSCLC

Room: Lehar 3-4

- **Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives**
Charles Butts, Canada & Frank Griesinger, Germany

07:30 - 08:30: Meet the Expert (MTE09) (Ticketed Session: €35,00)

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: Stolz 1

- **Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors in Advanced NSCLC**
Jie Wang, China & Sabine Zöchbauer-Müller, Austria

07:30 - 08:30: Special Session (WS08): CAP/IASLC/AMP Guidelines for Molecular Testing in Lung Cancer

Room: Strauss 1

Speakers and Chairs: Ming-Sound Tsao, Canada & Dr. Yasushi Yatabe, Japan

07:30 - 08:30: Industry Supported Symposia: ISS Orchestrating Progress for Patients with Squamous Cell Lung Cancer - Eli Lilly and Company

Room: Strauss 2

Chair: Silvia Novello, Italy

- **07:30 - Squamous Cell Lung Cancer - A Different Tune**
Johan Vansteenkiste, Belgium
- **07:45 - Hitting the Right Notes for Clinical Efficacy**
John Gosney, UK
- **08:00 - Fine Tuning Patient Outcomes by Selecting the Right Treatment, for the Right Patient, at the Right Time**
David Gandara, USA

- 08:15 - **Harmonising Patients Understanding of their Diagnosis and Treatment Plan: Introducing the Squamous Cell Lung Cancer Patient Booklet**
Silvia Novello, Italy
- 08:20 - **Discussion**

07:30 - 08:30: Industry Supported Symposium: ISS The Changing Treatment Paradigm After Progression in Advanced EGFR-Mutated NSCLC - PeerVoice

Room: Stolz 2

Chair: James Chih-Hsin Yang, Taiwan

- 07:30 - **Introduction: The Path Forward in Advanced EGFR-Mutated NSCLC**
James Chih-Hsin Yang, Taiwan
- 07:35 - **Emerging Algorithm for Advanced EGFR-Mutated NSCLC After Progression**
Howard West, USA & Anders Mellempgaard, Denmark
- 07:45 - **Best Practices for Managing Advanced EGFR-Mutated NSCLC After Progression**
Howard West, USA & Anders Mellempgaard, Denmark
- 07:55 - **Panel Discussion: Overcoming Obstacles Managing Advanced EGFR-Mutated NSCLC After Progression**
All Faculty
- 08:15 - **Conclusions & Questions**
James Chih-Hsin Yang, Taiwan

08:45 - 09:00: Official Opening of the IASLC 17th World Conference on Lung Cancer (PL02a)

Room: Hall D (Plenary Hall)

Chairs: Robert Pirker, Austria, David Carbone, USA & Fred Hirsch, USA

- **Welcome Address**
Heinz Fischer, Former Federal President of the Republic of Austria (2004-2016)

09:00 - 10:20: Plenary Session (PL02b): Tobacco Control

Chairs: Carolyn Dresler, USA & Peter Goldstraw, UK

- 09:00 - **PL02b.01: Implementing Tobacco Control Measures in Uruguay**
Tabaré Vázquez, Uruguay
- 09:25 - **PL02b.02: Framework Convention on Tobacco Control: Its impact on Global Health**
Vera da Costa e Silva, Switzerland
- 09:45 - **PL02b.03: Free Trade & Investment Agreement Threatens Public Health**
Zariah Zain, Malaysia
- 10:00 - **PL02b.04: Tobacco Control**
Luke Clancy, Ireland

10:25 - 11:00: Poster Session

Room: Hall B (Poster Area)

10:30: Press Conference (PR02)

Room: Schubert 1

11:00 - 12:30: Educational Session (ED01): Biology of Lung Cancer

Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy

Room: C1

Chairs: Rafael Rosell, Spain & Martin Filipits, Austria

- 11:00 - 11:25: **Understanding Biology: The Road to Cure?**
David Carbone, USA
- 11:25 - 11:50: **Tobacco Carcinogens and Lung Cancer Susceptibility**
Stephen Hecht, USA
- 11:50 - 12:15: **Insights from TCGA**
Ramaswamy Govindan, USA

11:00 - 12:30: Educational Session (ED02): Palliative Care in Lung Cancer: A Global Challenge

Track: Palliative Care/Ethics

Room: Strauss 3

Chairs: Jeffrey Crawford, USA & Jean Klastersky, Belgium

- 11:00 - **Palliative Care and its Importance for Patients with Lung Cancer**
Herbert Watzke, Austria
- 11:20 - **Palliative Care in South America**
Luis Alberto Mas Lopez, Peru
- 11:35 - **Palliative Care in India**
Gouri Shankar Bhattacharyya, India
- 11:50 - **Palliative Care in South-East Asia**
Richard B. L. Lim, Malaysia
- 12:05 - **Palliative Care in Iran**
Reza Malayeri, Iran

11:00 - 12:30: Science Session (SC01): Staging Before and After Induction Therapy for N2 Disease

Track: Radiology/Staging/Screening | Locally Advanced NSCLC

Room: Lehar 3-4

Chairs: Bernward Passlick, Germany & Gerhard Mostbeck, Austria

- 11:00 - **The Importance of Mediastinal Down-Staging During Induction Therapy of N2 Disease**
Paul de Leyn, Belgium
- 11:20 - **PET-CT for Response Assessment During Induction Therapy of N2 NSCLC**
Christoph Pöttgen, Germany
- 11:35 - **EBUS/EUS for Staging During Induction Therapy of N2 NSCLC**
Franz Stanzel, Germany
- 11:50 - **The Role of Mediastinoscopy in Induction Therapy of N2 NSCLC**
Sergi Call, Spain
- 12:05 - **Video-Thoracoscopy for Staging of N2 NSCLC During Induction Therapy**
Thomas D'Amico, USA
- 12:20 - **Q&A**

11:00 - 12:30: Science Session (SC02): Multifocal Lung Cancer

Track: Pulmonology | Radiology/Staging/Screening

Room: Strauss 1

Chairs: Giulia Veronesi, Italy & Saulus Cicenias, Lithuania

- 11:00 - **Multiple Primary Lung Cancers Versus Lung Metastases: Pathological Differential Diagnosis**
Erik Thunnissen, The Netherlands
- 11:20 - **Surgical Choices for Patients with Multifocal Lung Cancer**

Scott Swanson, USA

- 11:50 - **Surgery for Ground Glass Opacity: Sublobar Resection?**
Shun-Ichi Watanabe, Japan
- 12:10 - **Interactive Presentation of Clinical Cases with Multifocal Lung Cancer**
Alper Toker, Turkey

11:00 - 12:30: Science Session (SC03): Advances in Radiation Oncology

Track: Radiotherapy

Room: Strauss 2

Chairs: Hak Choy, USA & Richard Pötter, Austria

- 11:00 - **Advances in Stereotactic Body Radiotherapy**
Matthias Guckenberger, Switzerland
- 11:20 - **Proton Therapy of Lung Cancer**
Jeffrey Bradley, USA
- 11:40 - **Carbon-Ion Therapy of Lung Cancer**
Yuko Nakayama, Japan
- 11:55 - **Molecular Predictive Biomarkers for Radiotherapy Outcome in Lung Cancer**
Walter Curran, USA
- 12:10 - **Radiotherapy Combined with Targeted Therapies or Immunotherapy**
Rafal Dziadziuszko, Poland

11:00 - 12:30: Science Session (SC04): EGFR Tyrosine Kinase Inhibitors: A Model for Successful Drug Development

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: C7

Chairs: Sumitra Thongprasert, Thailand & Oliver Gautschi, Switzerland

- 11:00 - **First- and Second Generation EGFR Tyrosine Kinase Inhibitors**
James Chih-Hsin Yang, Taiwan
- 11:20 - **Management of Resistance to EGFR Tyrosine Kinase Inhibitors**
Tetsuya Mitsudomi, Japan
- 11:40 - **Sequencing of EGFR Tyrosine Kinase Inhibitors**
Keunchil Park, South Korea
- 12:00 - **Liquid Biopsies for Dynamic Monitoring of EGFR Mutations in Lung Cancer**
Martin Schuler, Germany
- 12:20 - **Q&A**

11:00 - 12:30: Science Session (SC05): Novel Drugs in Thoracic Cancers

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: C2

Chairs: Roy Herbst, USA & Nagahiro Saijo, Japan

- 11:00 - **Immunotherapy in Malignant Pleural Mesothelioma**
Raffit Hassan, USA
- 11:20 - **Novel Cytotoxic Drugs in Lung Cancer**
Jean-Charles Soria, France
- 11:40 - **Novel Tyrosine Kinase Inhibitors in Lung Cancer**
Caicun Zhou, China
- 12:00 - **Lung Cancer Vaccines: An Update**
Elisabeth Quoix, France

- 12:20 - Q&A

11:00 - 12:20: Interactive Session (IA01): Multidisciplinary Diagnosis of Lung Cancer in the Era of Molecular Medicine

Track: Biology/Pathology | Radiology/Staging/Screening

Room: Stolz 1

Chairs: Kwun Fong, Australia & Ales Ryska, Czech Republic

- 11:00 - **The Role Pathology for Diagnosis and Treatment of Lung Cancer**
Helmut Popper, Austria
- 11:20 - **What Endoscopic Techniques can Contribute for Specimen Acquisition**
Arschang Valipour, Austria
- 11:40 - **What Every Lung Pathologist Needs to Know About Thoracic Surgery**
Hans Hoffman, Germany
- 12:00 - **Does Cytological Material Fit All - Lessons from EBUS/Bronchoscopy**
Wlodzimierz Olszewski, Poland

11:00 - 12:30: Interactive Session: IA02 Staging* (Ticketed session: €35,00)

Group I (Space is limited to 20 participants)

Track: Radiology/Staging/Screening

Room: Schubert 3

Coordinators: Karin Dieckmann, Austria & Helmut Prosch, Austria

Trainers: Libor Havel, Czech Republic, Anna Kerpel-Fronius, Hungary & Elisabeth Stiefsohn, Austria

**Please note that this session is a duplicate of the session on Tuesday*

11:00 - 12:30: Nurses Session (NU01): Prevention

Track: Nurses | Epidemiology/Tobacco Control and Cessation/Prevention

Room: Schubert 5

Chairs: Liz Darlison, UK & Iveta Nohavova, Czech Republic

- 11:00 - **China at the Crossroads: Findings from the ITC China Project on the Current State of Tobacco Control in China**
Geoffrey Fong, Canada
- 11:20 - **Global View of Smoking Cessation**
Stella Bialous, USA
- 11:40 - **The Role of Oncology Nurses & Smoking Cessation**
Iveta Nohavova, Czech Republic
- 12:00 - **Stigma in Lung Cancer**
Janine Cataldo, USA
- 12:15 - **Indigenous Population with Lung Cancer**
Gail Garvey, Australia

11:00 - 12:30: Patient Advocacy Session (PA01): Lung Cancer Diagnosis and Care: Identifying and Improving Community Standards

Track: Patient Support and Advocacy Groups

Room: Schubert 6

Chairs: Bonnie Addario, USA & Blaž Bajec, Slovenia

- 11:00 - **The Importance of Patient Access to Molecular Testing and Novel Therapies**
Janet Freeman-Daily, USA
- 11:20 - **The Route to Diagnosis: Impacting Survival by Changing the System**

- Thomas Newsom-Davis, UK
- 11:40 - **Establishing a Paradigm for High Quality Lung Cancer Treatment**
David LeDuc, USA
 - 12:00 - **Nurse-Led Lung Cancer Support Service**
Claire Mulvihill, Australia
 - 12:15 - **Lung Cancer Management in Turkey**
Seda Kansu, Turkey

11:00 - 12:30: Concurrent Abstract Sessions

11:00 - 12:30: Oral Session (OA01): Risk Assessment and Follow up in Surgical Patients

Room: Schubert 2

Chairs: Eric Lim, UK & Wen-Zhao Zhong, China

- 11:00 - **OA01.01: Institutional-Based Differences in the Quality and Outcomes of US Lung Cancer Resections**
Raymond Osarogiagbon, USA
- 11:10 - **OA01.02: A Lung Cancer Surgical Mortality Risk-Prediction Algorithm to Inform Lung Cancer Screening Shared Decision-Making**
Joshua Roth, USA
- 11:20 - **OA01.03: Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Stage I NSCLC Patients: A Competing Risk Analysis**
Takashi Eguchi, USA
- 11:30 - **OA01.04: Discussant:**
Alessandro Brunelli, UK
- 11:45 - **OA01.05: The Impact of Lung Age on Postoperative Complications in Patients with Lung Cancer Combined with Pulmonary Fibrosis and Emphysema** - Masahito Naito, Japan
- 11:55 - **OA01.06: Early Post-Operative Ambulation after Thoracic Surgery - The WAVE Experience**
Sandeep Khandhar, USA
- 12:05 - **OA01.07: Alternative Follow-Up Methods Based on Recurrence Patterns after Surgery for Non-Small Cell Lung Cancer** - Katsuya Watanabe, Japan
- 12:15 - **OA01.08: Discussant:** Thomas Klikovits, Austria

11:00 - 12:30: Oral Session (OA02): Novel Targets and Biomarkers in Malignant Pleural

Mesothelioma

Room: Stolz 2

Chairs: Luis Raez, USA & Marko Jakopovic, Croatia

- 11:00 - **OA02.01: The microRNA-15/16 Family Regulates Tumour Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma**
Karin Schelch, Australia
- 11:10 - **OA02.02: Gremlin-1 is a Key Regulator of the Invasive Phenotype in Mesothelioma**
Katri Koli, Finland
- 11:20 - **OA02.03: Circulating Fibroblast Growth Factor 18 is Elevated in Malignant Pleural Mesothelioma Patients - A Multi-Institutional Study**
Yawen Dong, Austria
- 11:30 - **OA02.04: Discussant:**
Michaela Kirschner, Switzerland

- 11:45 - **OA02.05: Expression of miR-223 in Mesothelioma Xenografts Originates from Stromal Cells in the Tumour Microenvironment**
Kadir Sarun, Australia
- 11:55 - **OA02.06: Converting Tumor-Mediated PD-L1 Inhibition into CAR T-Cell Costimulation to Potentiate Thoracic Cancers Immunotherapy**
Prasad Adusumilli, USA
- 12:05 - **OA02.07: Characterization of the Tumor Microenvironment and Investigation of Immune Checkpoint Expression in Malignant Pleural Mesothelioma**
Elly Marcq, Belgium
- 12:15 - **OA02.08: Discussant:**
Michael Grusch, Austria

11:00 - 12:30: Oral Session (OA03): Immunotherapy Checkpoint Inhibitors in Advanced NSCLC
Room: C8

Chairs: Lucio Crinò, Italy & Tanja Čufer, Slovenia

- 11:00 - **OA03.01: First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012**
Scott Gettinger, USA
- 11:10 - **OA03.02: Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1-Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study**
Marina Garassino, Italy
- 11:20 - **OA03.03: JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC**
Claire Verschraegen, USA
- 11:30 - **OA03.04: Discussant:**
Edward Garon, USA
- 11:45 - **OA03.05: Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057**
Solange Peters, Switzerland
- 11:55 - **OA03.06: Evaluation of Toxicity Profile of PD-1 versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer (NSCLC)**
Rathi Pillai, USA
- 12:05 - **OA03.07: KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab**
Roy Herbst, USA
- 12:15 - **OA03.08: Discussant:**
Paul Mitchell, Australia

11:00 - 12:30: Oral Session (OA04): Epidemiology and Prevention of Lung Cancer

Room: Schubert 4

Chairs: Luboš Petruželka, Czech Republic & Surendra Shastri, India

- 11:00 - **OA04.01: Educational and Wealth Inequalities in Tobacco Use among Men and Women in 54 Low-And-Middle-Income Countries**
Chandrashekhara Sreeramareddy, Malaysia
- 11:10 - **OA04.02: Smoking Behavior in Patients with Early Stage Non-Small Cell Lung Cancer: A Report from ECOG-ACRIN 1505 Trial**
Suresh Ramalingam, USA

- 11:20 - **OA04.03: Preliminary Results of a Low Cost Intervention to Improve Tobacco Cessation Practices within a Large University Health System**
Douglas Arenberg, USA
- 11:30 - **OA04.04 Discussant:** Gilberto Lopes, Brazil
- 11:45 - **OA04.05: Chronic Inflammation, NSAIDS and the Risk of Lung Cancer Death** - Marisa Bittoni, USA
- 11:55 - **OA04.06: Examining Pleiotropic Associations of Genetic Risk Variants for Chronic Obstructive Pulmonary Disease with Lung Cancer Risk**
Lori Sakoda, USA
- 12:05 - **OA04.07: Clinical Characteristics of Lung Adenocarcinoma in the Young: Results from the Genomics of Young Lung Cancer Study**
Barbara Gitlitz, USA
- 12:15 - **OA04.07: Discussant:**
Ruxandra Ulmeanu, Romania

11:00 - 12:30: Mini Oral Session (MA01): Improvement and Implementation of Lung Cancer Screening

Room: Lehar 1-2

Chairs: Michael Studnicka, Austria & Christine Berg, USA

- 11:00 - **MA01.01: Detection of Lung Cancer and EGFR Mutations by Electronic Nose System**
Nir Peled, Israel
- 11:06 - **MA01.02: Non-Invasive LuCED® Test for Endobronchial Dysplasia, Enabling Chemoprevention Therapy with Drugs Such as Iloprost**
Javier Zulueta, USA
- 11:12 - **MA01.03: The Non-Invasive LuCED® Test for Detection of Early Stage Lung Cancer**
Javier Zulueta, USA
- 11:18 - **MA01.04: Discussant:**
Jiri Votruba, Czech Republic
- 11:30 - **MA01.05: Predictive Performances of NELSON Screening Program Based on Clinical, Metrological and Population Statistics**
Hubert Beaumont, France
- 11:36 - **MA01.06: Long-Term Follow-Up of Small Pulmonary Ground-Glass Nodules Stable for 3 Years: Proper Follow-Up Period and Risk Factors for Subsequent Growth**
Choon-Taek Lee, South Korea
- 11:42 - **MA01.07: Influence of Nodule Morphology on Inter-Reader Variability of Volume and Diameter Measurements in CT Lung Cancer Screening**
Marjolein Heuvelmans, Netherlands
- 11:48 - **MA01.08: Discussant:**
Ricardo Sales dos Santos, Brazil
- 12:00 - **MA01.09: Mortality, Survival and Incidence Rates in the ITALUNG Randomised Lung Cancer Screening Trial (ITALY)**
Eugenio Paci, Italy
- 12:06 - **MA01.10: Performance of ACR Lung-RADS in the 1st Brazilian Lung Cancer Screening Trial (BRELT1)**
Ricardo Santos, Brazil
- 12:12 - **MA01.11: Implementation of LDCT Lung Cancer Screening into Practice. Results of Regional Early Detection Program**
Maciej Bryl, Poland
- 12:18 - **MA01.12: Discussant:**

David Yankelevitz, USA

12:45 - 14:15: Industry Supported Symposia: ISS Immuno-Oncology and Lung Cancer: Emerging Data and Recent Developments - Bristol-Myers Squibb

Room: Hall D (Plenary Hall)

Chair: Matthew Hellmann, USA

- 12:45 - **Welcome & Introduction**
Matthew Hellmann, USA
- 12:55 - **Developments in the Use of I-O Monotherapy in Lung Cancers**
Enriqueta Felip, Spain
- 13:10 - **Rationale for Studying I-O Combo Therapies to Address Unmet Needs in Lung Cancer**
Matthew Hellmann, USA
- 13:35 - **Clinical Lessons Learned for the Use of I-O Therapies**
Jürgen Wolf, Germany
- 13:55 - **Close & Outlook**
Matthew Hellmann, USA
- 14:00 - **Audience Q&A**
Full Panel

14:15 - 15:45: Concurrent Abstract Sessions

14:15 - 15:45: Oral Session (OA05): Treatment Advances in SCLC

Room: Strauss 2

Chairs: Andrea Ardizzoni, Italy & Jean Luis Pujol, France

- 14:15 - **OA05.01: Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE-028**
Patrick Ott, USA
- 14:25 - **OA05.02: Anti-Tumor Immunity is a Key Determinant of SCLC Survivorship**
Farhad Kosari, USA
- 14:35 - **OA05.03: Single-Agent Rovalpituzumab Tesirine, a Delta-Like Protein 3 (DLL3)-Targeted Antibody-Drug Conjugate (ADC), in Small-Cell Lung Cancer (SCLC)**
David Spigel, USA
- 14:45 - **OA05.04: Discussant:**
Leora Horn, USA
- 14:55 - **OA05.05: Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)**
Taofeek Owonikoko, USA
- 15:05 - **OA05.06: Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial**
Marianna Christodoulou, UK
- 15:15 - **OA05.07: Prognostic Value of Circulating Tumour Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial**
Fabiola Fernandez-Gutierrez, UK
- 15:25 - **OA05.08: Discussant:**
Jens Benn Sørensen, Denmark

14:15 - 15:45: Oral Session (OA06): Prognostic & Predictive Biomarkers

Room: Strauss 1

Chairs: Frances Shepherd, Canada & Yasushi Yatabe, Japan

- 14:15 - **OA06.01: Clinical Utility of Circulating Tumor DNA (ctDNA) Analysis by Digital next Generation Sequencing of over 5,000 Advanced NSCLC Patients**
Philipp Mack, USA
- 14:25 - **OA06.02: Mutational Load Predicts Survival in LDCT Screening-Detected Lung Cancers**
Gabriella Sozzi, Italy
- 14:35 - **OA06.04: Transcriptome Analysis of ATM-Deficient NSCLC**
Lars Petersen, Canada
- 14:45 - **OA06.05: Discussant:**
Ross Soo, Singapore
- 15:00 - **OA06.05: Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial**
Jean-Charles Soria, France
- 15:10 - **OA06.06: Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC)**
Sara Pilotto, Italy
- 15:20 - **OA06.07: Evaluating Genomic Signatures Predicting Veliparib Sensitivity in Non-Small Cell Lung Cancer (NSCLC)**
Lei He, USA
- 15:30 - **OA06.08: Discussant:**
Maya Gottfried, Israel

14:15 - 15:45: Oral Session (OA07): Lymph Node Metastases and Other Prognostic Factors for Local Spread

Room: Stolz 1

Chairs: Vítězslav Kolek, Czech Republic & TBD

- 14:15 - **OA07.01: Incidence, Local Distribution and Impact of pN2 Skip Metastasis in Patients Undergoing Curative Resection for NSCLC**
Ariane Steindl, Austria
- 14:25 - **OA07.02: Omitting Intrapulmonary Lymph Node Retrieval May Affect the Oncological Outcome of pN0 Lung Cancer Patients: A Propensity Score Match Analysis**
Nan Wu, China
- 14:35 - **OA07.03: Prognostic Significance of Micrometastases in Mediastinal Lymph Nodes of Patients With Radically Resected Non-Small Cell Lung Cancer**
Paweł Gwóźdź, Poland
- 14:45 - **OA07.04: Discussant:**
Yi Long Wu, China
- 15:00 - **OA07.05: Prognostic Impact of Pleural Lavage Cytology (PLC): Significance of PLC after Lung Resection**
Shinya Katsumata, Japan
- 15:10 - **OA07.06: In Early-Stage Lung Adenocarcinomas, Survival by Tumor Size (T) is Further Stratified by Tumor Spread through Air Spaces**
Takashi Eguchi, USA
- 15:20 - **OA07.07: Discussant:**
Mark Krasnik, Denmark

14:15 - 15:45: Mini Oral (MA02): RNA in Lung Cancer

Room: Stolz 2

Chairs: Elisabeth Brambilla, France & Masayuki Noguchi, Japan

- 14:15 - **MA02.01: Extracellular Vesicle miRNAs Regulate Gene Expression in Local Lung Adenocarcinoma Endothelial Cells**
James Lawson, Canada
- 14:21 - **MA02.02: A Novel 5-miR Signature Shows Promise as a Diagnostic Tool and as a Predictor of Cisplatin Response in NSCLC**
Martin Barr, Ireland
- 14:27 - **MA02.03: Expression of Oncofetal miRNAs Inactivates NFIB, a Developmental Transcription Factor Linked to Tumour Aggressiveness in Lung Adenocarcinoma**
Daiana Becker-Santos, Canada
- 14:33 - **MA02.04: Discussant:**
Luis Montuenga, Spain
- 14:45 - **MA02.05: Distinct Angiogenic microRNA-mRNA Expression Profiles among Subtypes of Lung Adenocarcinoma**
Mirella Giordano, Italy
- 14:51 - **MA02.06: Discussant:**
Rafael Rosell, Spain
- 15:03 - **MA02.07: Evaluation of Exosomal miRNAs from Plasma as Potential Biomarker for NSCLC**
Xiance Jin, China
- 15:09 - **MA02.08: Deregulation of Cis-Acting Long Non-Coding RNAs in Non-Small Cell Lung Cancer**
Adam Sage, Canada
- 15:15 - **MA02.09: Long Non-Coding RNA Expression from Pseudogene Loci as a Novel Mechanism of Cancer Gene Regulation**
Greg Stewart, Canada
- 15:21 - **MA02.10: Discussant:**
Bojan Zaric, Serbia

14:15 - 15:45: Mini Oral (MA03): Epidemiology, Risk Factors and Screening

Room: Lehar 3-4

Chairs: Nazmi Bilir, Turkey & Horst Olschewski, Austria

- 14:15 - **MA03.01: Gender Disparities in Non-Small Cell Lung Cancer: A Systematic Review**
Gwyn Bebb, Canada
- 14:21 - **MA03.02: Lung Cancer in Women 1929 to 2016: Cold-Blooded Origins of an Epidemic**
Fred Grannis, USA
- 14:27 - **MA03.03: High Risk for Second Primary Lung Cancer in Taiwanese Early-Onset Female Breast Cancer Patients**
Pei-Ying Lin, Taiwan
- 14:33 - **MA03.04: Discussant:**
Ana Jovicevic, Serbia
- 14:45 - **MA03.05: Cost Effectiveness Analysis of CT vs Chest X-Ray (CXR) vs No Screening for Lung Cancer (LC) in the PLCO and NLST Randomized Population Trials (RPTs)**
John Paul Flores, USA
- 14:51 - **MA03.06: Cost Effectiveness of Chest Scan Screening for Lung Cancer in Abestos Occupational Exposure Subjects: A Model Based Study**
Christos Chouaid, France
- 14:57 - **MA03.07: Discussant:**
Thierry Berghmans, Belgium

- 15:09 - **MA03.08: Quantifying Survival in Early-Stage NSCLC: Implications of Relative Survival vs Cause-Specific Survival**
Kay See Tan, USA
- 15:15 - **MA03.09: Retrospective Predictive Performance of a Lung Cancer Screening Risk Prediction Model in a Clinical Lung Cancer Screening Program**
Andrea Borondy Kitts, USA
- 15:21 - **MA03.10: Educational Level and the Management and Outcome in Non-Small Cell Lung Cancer: A Nationwide Study (Sweden)**
Anna Öjdahl Boden, Sweden
- 15:27 - **MA03.11: Discussant:**
Oleg Pikin, Russia

14:30 - 15:15: Meet the JTO Editor

Room: Schubert 4

Chair: Alex Adjei, USA

14:30 - 15:45: Educational Session (ED03): Global Tobacco Control Policies: Advances & Challenges

Track: Epidemiology/Tobacco Control and Cessation/Prevention

Room: C1

Chairs: Gábor Kovács, Hungary & Xiuyi Zhi, China

- 14:30 - **Tobacco Control in the Middle East**
Feras Hawari, Jordan
- 14:50 - **The Australian Tobacco Control Strategy: Lessons Learned**
Mike Daube, Australia
- 15:10 - **Tobacco Control and Lung Cancer in Africa**
Lekan Ayo-Yusuf, South Africa
- 15:30 - **Trumping Big Tobacco**
Bronwyn King, Australia

14:30 - 15:45: Educational Session (ED04): Bronchopulmonary Carcinoids

Track: SCLC/Neuroendocrine Tumors

Room: Lehar 1-2

Chairs: Vera Gorbunova, Russia & Jörg Hutter, Austria

- 14:30 - **Surgery in Bronchopulmonary Typical and Atypical Carcinoids**
Pier Luigi Filosso, Italy
- 14:50 - **Systemic Therapy of Bronchopulmonary Typical and Atypical Carcinoids: Current Status and Perspectives**
Eric Baudin, France

14:30 - 15:45: Interactive Session (IA03): What are the Lung Cancer Patients Needs in the Different Countries?

Track: Patient Support and Advocacy Groups (Interactive Session)

Room: Schubert 2

Chairs: Stefania Vallone, Italy & Ingeborg Beunders, Austria

Patient needs around the world. Participants will place notes showing the needs in the countries on a map, which will be followed by a discussion. Outcome of the interactive session will be presented at the end of the conference by Stefania Vallone and Ingeborg Beunders.

14:30 - 15:45: Pro-Con Session (PC01): Invasive Mediastinal Staging for N2 Disease

Track: Radiology/Staging/Screening | Locally Advanced NSCLC

Room: C2

Chairs: Walter Weder, Switzerland & Helmut Prosch, Austria

- 14:30 - **Introduction & Vote**
Helmut Prosch, Austria
- 14:40 - **Invasive Staging and Restaging**
Christophe Doods, Belgium
- 15:00 - **No Invasive Staging Nor Restaging**
Eric Lim, UK
- 15:20 - **Discussion & Vote**
Walter Weder, Switzerland

14:30 - 15:45: Science Session (SC06): Novel Therapies in Malignant Pleural Mesothelioma and Thymic Malignancies

Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

Room: Strauss 3

Chairs: Anna Nowak, Australia & Takashi Nakano, Japan

- 14:30 - **Comprehensive Genomic Analysis of Malignant Pleural Mesothelioma**
Raphael Bueno, USA
- 14:50 - **Stratified Therapy for Malignant Pleural Mesothelioma**
Dean Fennel, UK
- 15:10 - **Intraoperative Therapies in Malignant Pleural Mesothelioma**
Isabelle Opitz, Switzerland
- 15:30 - **Immunotherapy of Malignant Pleural Mesothelioma and Thymic Malignancies: The End of the Beginning?**
Jan van Meerbeeck, Belgium

14:30 - 15:45: Poster Session with Presenters Present (P1)

Room: Hall B (Poster Area)

- [Click here for the IASLC WCLC 2016 Poster Program >>](#)

16:00 - 17:30: Educational Session (ED05): The 8th Edition of the TNM Staging System

Track: Radiology/Staging/Screening

Room: C1

Chairs: Peter Goldstraw, UK & Ramon Rami-Porta, Spain

- 16:00 - **What's New in Lung Cancer Staging?**
Hisao Asamura, Japan
- 16:25 - **Update on the Mesothelioma Staging System**
Valerie Rusch, USA
- 16:45 - **The Thymic Epithelial Tumor Staging System**
Kazuya Kondo, Japan
- 17:05 - **What's New in Esophageal Cancer Staging?**
Thomas Rice, USA

16:00 - 17:30: Educational Session (ED06): Symptom Management in Lung Cancer

Track: Palliative Care/Ethics

Room: Stolz 1

Chairs: Richard Gralla, USA & Reza Malayeri, Iran

- 16:00 - **Causes and Management of Dyspnea**
Otto Burghuber, Austria
- 16:15 - **Endobronchial and Pleural Palliation**
Arschang Valipour, Austria
- 16:30 - **Pain Management**
Vera Hirsh, Canada
- 16:45 - **Biology and Management of Tumor Cachexia**
Jeffrey Crawford, USA
- 17:00 - **Surgery for Symptom Relief**
Shahrokh Taghavi, Austria
- 17:15 - **Decisions in Case of Intractable Symptoms**
Jean Klastersky, Belgium

16:00 - 17:30: Science Session (SC07): New Challenges for Lung Cancer: Waterpipes and E-Cigarettes

Track: Epidemiology/Tobacco Control and Cessation/Prevention

Room: Stolz 2

Chairs: Martina Pötschke-Langer, Germany & Manfred Neuberger, Austria

- 16:00 - **Carcinogen Exposure from Waterpipe and ENDS (Electronic Nicotine Delivery Systems)**
Alan Shihadeh, Lebanon
- 16:25 - **Health Effects of E-Cigarette Aerosol and Nicotine Exposure on the Respiratory System**
Charlotta Pisinger, Denmark
- 16:50 - **Connections of Nicotine to Cancer and its Influence on Cancer Treatment**
Sergei Grando, USA
- 17:15 - **Q&A**

16:00 - 17:30: Science Session (v): IASLC- ESTS Joint Symposium: The Borderline Patient

Track: Surgery | Pulmonology

Room: C7

Chairs: Jaroslaw Kuzdzal, Poland & TBD

- 16:00 - **Impact and Management of Co-Morbidities**
Alessandro Brunelli, UK
- 16:20 - **Emphysema as a Limiting Factor for Lung Resection: How Far We Can Go?**
Walter Weder, Switzerland
- 16:40 - **Surgical Issues in the Borderline Patient: Sublobar versus Standard Resection**
David Harpole, USA
- 17:00 - **SABR Versus Surgery**
Norihiko Ikeda, Japan
- 17:20 - **Q&A**

16:00 - 17:30: Science Session (SC09): Radiotherapy for a Global Cancer

Room: C8

Track: Radiotherapy | Regional Aspects/Health Policy/Public Health

Chairs: Yuko Nakayama, Japan & Deniz Yalman, Turkey

- 16:00 - **Global Access To Radiotherapy: Are We There?**
David Palma, Canada
- 16:20 - **The Quest for High Quality Affordable Radiotherapy in Developing Countries**
Hak Choy, USA
- 16:40 - **Machine Learning for Individualized Radiotherapy Prescription**
Phillippe Lambin, The Netherlands
- 17:00 - **Radiotherapy in China**
Luhua Wang, China
- 17:20 - **Q&A**

16:00 - 17:30: Science Session (SC10): Squamous Cell NSCLC

Track: Chemotherapy/Targeted Therapy/Immunotherapy | Advanced NSCLC

Room: Strauss 3

Chairs: David Gandara, USA & Martin Sebastian, Germany

- 16:00 - **Genetic Alterations as Potential Therapeutic Targets**
Roman Thomas, Germany
- 16:20 - **EGFR Mutations in Indian Patients with Squamous Cell NSCLC**
Kumar Prabhash, India
- 16:40 - **Anti-EGFR Monoclonal Antibodies in Squamous Cell NSCLC**
Robert Pirker, Austria
- 17:00 - **Second-Line Therapy and Beyond in Squamous Cell NSCLC**
Silvia Novello, Italy
- 17:20 - **Q&A**

16:00 - 17:30: Science Session (SC11) ALK, ROS1 and Rare Mutations in NSCLC

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: Lehar 1-2

Chairs: Dong-Wan Kim, South Korea & Dragana Jovanovic, Serbia

- 16:00 - **Optimal Application & Sequence of ALK Inhibition Therapy**
Benjamin Solomon, Australia
- 16:20 - **Resistance to ALK Inhibitor Therapy**
Sai-Hong Ou, USA
- 16:40 - **ROS1 as a Therapeutic Target in Advanced NSCLC**
Jürgen Wolf, Germany
- 17:00 - **Rare Mutations in Lung Cancer**
Oliver Gautschi, Switzerland
- 17:20 - **Q&A**

16:00 - 17:30: Science Session (SC12): Anticancer Drug Development in the 21st Century

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: C2

Chairs: Lawrence Einhorn, USA & Kaoru Kubota, Japan

- 16:00 - **Establishment of EGFR Tyrosine Kinase Inhibitors: History and Lessons Learned for Future Drug Development**
Tony Mok, Hong Kong
- 16:25 - **Molecular-Based Therapy of Lung Cancer: The Way Forward?**

Charles Rudin, USA

- 16:45 - **Implications of Patient Selection: Are we Lost in Diversification?**
Yu Shyr, USA
- 17:05 - **Drug Development: The EMA Perspective**
Francesco Pignatti, UK
- 17:25 - **Q&A**

16:00 - 17:30: Interactive Session (IA04): Target Delineation* (Ticketed Session: €35,00)

Track: Radiotherapy

Room: Schubert 3

Coordinators: Karin Dieckmann, Austria & Helmut Prosch, Austria

Group I (Space is limited to 20 participants)

Trainers: Corinne Faivre-Finn, UK, Laurie Gaspar, USA, Billy Loo, USA

**Please note that this session is a duplicate of the session on Tuesday*

16:00 - 17:30: Nurses Session (NU02): Preparing Patients for Treatment

Track: Nurses

Room: Schubert 5

Chairs: Diana Borthwick, UK & Anne Fraser, New Zealand

- 16:00 - **Preparing Patients for Treatment. Providing Psychosocial Support for Lung Cancer Patients Preparing to Enter Treatment**
Andreja Cirila Škufca Smrdel, Slovenia
- 16:20 - **Preoperative Thoracic Surgery Patient Education Program Development**
Katherine Kuhns, USA
- 16:40 - **Ethical Decision Making**
Sabine Ruppert, Austria
- 17:00 - **Discussant**
Harald Titzer, Austria

16:00 - 17:30: Patient Advocacy Session (PA02): Access to Care - Equal Chances in the World?

Track: Patient Support and Advocacy Groups

Room: Schubert 6

Chairs: Christina Ng, Malaysia & Shani Shilo, Israel

- 16:00 - **Access to Care: USA**
Kim Norris, USA
- 16:15 - **Access to Care: South America**
Patricia Mondragon, Mexico
- 16:30 - **Access to Care: Malaysia**
Christina Ng, Malaysia
- 16:45 - **Access to Care: Europe**
Szymon Chrostowski, Poland
- 17:00 - **Access to Care: Australia**
Kerrie Callaghan, Australia
- 17:15 - **Access to Care: Israel**
Shani Shilo, Israel

16:00 - 17:30: Concurrent Abstract Sessions

16:00 - 17:30: Oral Session (OA08): Targeted Therapies in Brain Metastases

Room: Schubert 1

Chairs: David Ball, Australia & Rafal Dziadziuszko, Poland

- 16:00 - **OA08.01: Exploration of the Underlying Mechanisms of Leptomeningeal Metastasis in NSCLC Patients through NGS of Cerebrospinal Fluid**
Yun Fan, China
- 16:10 - **OA08.02: Phase II Study of Erlotinib in Advanced Non-Small Cell Lung Cancer Patients with Leptomeningeal Metastasis (LOGIK1101)**
Keiichi Ota, Japan
- 16:20 - **OA08.03: MET Copy Number Gain Associates with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR Mutant Lung Cancer**
Seiji Yano, Japan
- 16:30 - **OA08.04: Discussant:**
Roman Perez-Soler, USA
- 16:45 - **OA08.05: Efficacy and Cerebrospinal Fluid Concentration of Afatinib in NSCLC Patients with EGFR Mutation Developing Leptomeningeal Carcinomatosis**
Akihiro Tamiya, Japan
- 16:55 - **OA08.06: Brigatinib Activity in Patients with ALK+ NSCLC and Intracranial CNS Metastases in Two Clinical Trials**
Scott Gettinger, USA
- 17:05 - **OA08.07: BRAF-V600E Advanced Lung Adenocarcinoma with Leptomeningeal (LM) Disease Treated with Vemurafenib**
Maria Gabriela Fernandes, Portugal
- 17:15 - **OA08.08: Discussant:**
Niels Reinmuth, Germany

16:00 - 17:30: Mini Oral Session (MA04): HER2, P53, KRAS and Other Targets in Advanced NSCLC
Room: Lehar 3-4

Chairs: Baohui Han, China & TBD

- 16:00 - **MA04.01: Non-Amplification Mutation of ERBB2 in EGFR-Mutated Lung Cancer**
Jeffrey Ross, USA
- 16:06 - **MA04.02: Neratinib ± Temozolomide in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study**
Leena Gandhi, USA
- 16:12 - **MA04.03: Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC**
Shengxiang Ren, China
- 16:18 - **MA04.04: Discussant:**
Thanyanan Reungwetwattana, Thailand
- 16:30 - **MA04.05: P53 Non-Disruptive Mutation is a Negative Predictive Factor for OS and PFS in EGFR M+ NSCLC Treated with TKI**
Frank Griesinger, Germany
- 16:36 - **MA04.06: Signaling Networks in KRAS-Mutant Advanced NSCLC: A Complex Landscape Involving Immunoresponse, Inflammation and DNA Repair**
Sara Baglivo, Italy
- 16:42 - **MA04.07: Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy**
Ferdinandos Skoulidis, USA
- 16:48 - **MA04.08: Discussant:**
Julian Molina, USA

- 17:00 - **MA04.09: RICTOR Amplification in Non-Small Cell Lung Cancer: An Emerging Therapy Target**
Jeffrey Ross, USA
- 17:06 - **MA04.10: Lung Cancer Growth is Suppressed by CD26/DPP4-Inhibition via Enhanced NK Cell and Macrophage Recruitment**
Jae-Hwi Jang, Switzerland
- 17:12 - **MA04.11: Mechanistic Insights into CAR T-Cell Efficacy in the Treatment of Heterogenous Antigen Expressing Lung Adenocarcinoma**
Prasad Adusumilli, USA
- 17:18 - **MA04.12: Discussant:**
Ales Ryska, Czech Republic

16:00 - 17:30: Mini Oral Session: (MA05): Innovative Techniques in Pulmonology and the Impact on Lung Cancer

Room: Strauss 1

Chairs: Josef Eckmayr, Austria & Prasanta R. Mohapatra, India

- 16:00 - **MA05.01: Virtual Bronchoscopic Navigation-Guided Ultrathin Bronchoscopy for Diagnosing Peripheral Pulmonary Lesions**
Marta Diez-Ferrer, Spain
- 16:06 - **MA05.02: Electromagnetic Navigation Bronchoscopy: A Prospective, Global, Multicenter Analysis of 1000 Subjects with Lung Lesions**
Sandeep Khandhar, USA
- 16:06 - **MA05.03: A Single EBUS-TBNA Pass Yields Sufficient DNA for Targeted Molecular Testing in Lung Cancer**
Tracy Leong, Australia
- 16:12 - **MA05.04: Discussant:**
Vítězslav Kolek, Czech Republic
- 16:30 - **MA05.05: Genomic Profiles of Lung Cancer Associated with Idiopathic Pulmonary Fibrosis**
Ji An Hwang, South Korea
- 16:36 - **MA05.06: Diagnosis of Chronic Obstructive Pulmonary Disease in Lung Cancer - A Population Based Study**
John Goffin, Canada
- 16:42 - **MA05.07: Identifying Comorbid Disease on Chest CT Scans in a Lung Cancer Screening-Eligible Cohort**
James Finigan, USA
- 16:48 - **MA05.08: Discussant:**
Konstantinos Zarogoulidis, Greece
- 17:00 - **MA05.09: There is a Closely Relation between Exhaled Nitric Oxide and Radiation Pneumonitis**
Jiancheng Li, China
- 17:06 - **MA05.10: Cell-Free DNA Testing for EGFR Mutations in Clinical Practice - Facts and Figures from an Austrian Lung Cancer Center**
David Lang, Austria
- 17:12 - **MA05.11: Photodynamic Therapy for Peripheral Lung Cancer Using Composite-Type Optical Fiberscope of 1.0 Mm in Diameter**
Jitsuo Usuda, Japan
- 17:18 - **MA05.12: Discussant:**
Judit Moldvay, Hungary

16:00 - 17:30: Mini Oral Session (MA06): Locally Advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices

Room: Strauss 2

Chairs: Paul Van Houtte, Belgium & Milada Zemanova, Czech Republic

- 16:00 - **MA06.01: Overall Survival Characterization of Incidental N2 Non-Small Cell Lung Cancer over 14 Years at a Single Canadian Institution**
Cara Van Der Merwe, Canada
- 16:06 - **MA06.02: Does Pathological Staging Following Neoadjuvant Therapy (ypTNM) Reflect the Reality?**
Huseyin Melek, Turkey
- 16:12 - **MA06.03: Recurrence Dynamics after Trimodality Therapy (Neoadjuvant Chemoradiotherapy and Surgery) in Stage IIIa(N2) Lung Cancer**
Jung Hee Lee, South Korea
- 16:18 - **MA06.04: Discussant:**
Fan Yang, China
- 16:30 - **MA06.05: Screening for Brain Metastases in Patients with Stage III NSCLC, MRI or CT? A Prospective Study**
Janna Schoenmaekers, Netherlands
- 16:36 - **MA06.06: Tumor Microenvironment and Brain Metastases in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer**
Qin Zhang, China
- 16:42 - **MA06.07: Impact of Type 2 Diabetes Mellitus and Its Metabolic Control on Prognosis of Unresectable Non-Small Cell Lung Cancer Patients**
Milana Bergamino Sirvén, Spain
- 16:48 - **MA06.08: Discussant:**
Miroslaw Kozlowski, Poland
- 17:00 - **MA06.09: Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin & Chemo-Radiation in Stage III NSCLC. SLCG 10/02**
Dolores Isla, Spain
- 17:06 - **MA06.10: A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC**
Thomas Stinchcombe, USA
- 17:12 - **MA06.11: Phase II Study of Nimotuzumab + Concurrent Chemoradiotherapy (CRT) for Stage III Non-Small Cell Lung Cancer (NSCLC): 5-Year Follow-Up Results**
Kazushige Hayakawa, Japan
- 17:18 - **MA06.12: Discussant:**
Philip Bonomi, USA

17:45 - 19:15: Industry Supported Symposium: ISS Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus on EGFR-Targeted Therapy - A prIME Oncology satellite symposium supported by Boehringer Ingelheim Pharma GmbH & co. KG

Room: C7

Chair: Martin Schuler, Germany

- 17:45 - **Welcome & Warm-up Quiz**
Martin Schuler, Germany
- 17:50 - **Key Decision Points for Personalized Patient Care of Advanced Non-Small Cell Lung Cancer (NSCLC)**
Martin Schuler, Germany

- 18:00 - **Managing EGFR-Mutant Adenocarcinoma: What is the Optimal First-Line Approach?**
Barbara Melosky, Canada
- 18:20 - **Tackling Acquired Resistance to EGFR- Targeted Therapy: Evaluating Current and Emerging Treatment Strategies**
Keunchil Park, South Korea
- 18:40 - **Contemporary Management of Squamous Cell Carcinoma: What is the Role of EGFR-Targeted Therapy in the Era of Immunotherapy?**
Marianne Nicolson, UK
- 18:55 - **Quiz Questions Revisited and Questions from the Audience**
Martin Schuler, Germany
- 19:10 - **prIME Points™**
Martin Schuler, Germany

Tuesday, December 6, 2016

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH03)

Tracks: 05. Early Stage NSCLC
06. Locally Advanced NSCLC
10. Surgery

Room: Hall C1

Chairs: Walter Klepetko, Austria & Mark Krasnik, Denmark

- **Surgery:**
Saulus Cicenias, Lithuania
- **NSCLC stage I-II:**
Bernward Passlick, Germany
- **NSCLC stage III:**
Virginie Westeel, France

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH04)

Tracks: 03. Radiology/Staging/Screening
04. Pulmonology

Room: Hall C7

Chairs: Jiri Votruba, Czech Republic & Sylvia Hartl, Austria

- **Screening:**
James Jett, USA
- **Radiology/Staging:**
TBD
- **Pulmonology:**
Edgar Smit, The Netherlands

07:30 - 08:30: Meet the Expert (MTE10) (Ticketed Session: €35,00)

Track: Biology/Pathology

Room: Schubert 1

- **Unique Biologic Aspects of Tobacco-Induced Lung Cancer**
Mauro Papotti, Italy

07:30 - 08:30: Meet the Expert (MTE11) (Ticketed Session: €35,00)

Track: Biology/Pathology

Room: Schubert 2

- **The Clinical Impact of the 2015 WHO Classification of Lung Tumors**
Andrew Nicholson, UK & Masayuki Noguchi, Japan

07:30 - 08:30: Meet the Expert (MTE12) (Ticketed Session: €35,00)

Track: Biology/Pathology

Room: Schubert 4

- **Clinically Relevant Signal Transduction Pathways**
Ming-Sound Tsao, Canada & Balazs Dome, Austria

07:30 - 08:30: Meet the Expert (MTE13) (Ticketed Session: €35,00)

Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy

Room: Schubert 5

- **Basic Immunology for the Clinician**
Marcin Moniuszko, Poland & Edgardo Santos, USA

07:30 - 08:30: Meet the Expert (MTE14) (Ticketed Session: €35,00)

Track: Radiology/Staging/Screening

Room: Schubert 6

- **How to Implement Screening/Early Detection in Routine Practice**
Harry J De Koning, The Netherlands

07:30 - 08:30: Meet the Expert (MTE15) (Ticketed Session: €35,00)

Track: Radiology/Staging/Screening | Surgery

Room: Strauss 1

- **Lymph Node Mapping in Lung Cancer**
Kenji Suzuki, Japan & David Waller, UK

07:30 - 08:30: Meet the Expert (MTE16) (Ticketed Session: €35,00)

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: Strauss 2

- **Precision Medicine in NSCLC: Lessons Learned and Perspectives**
Christian Manegold, Germany & Terufumi Kato, Japan

07:30 - 08:30: Meet the Expert (MTE17) (Ticketed Session: €35,00)

Track: Advanced NSCLC | Chemotherapy/Targeted Therapy/Immunotherapy

Room: Strauss 3

- **Maintenance Therapy Versus Early Second-Line Therapy in Advanced NSCLC**
Tudor Ciuleanu, Romania & Panos Fidias, USA

07:30 - 08:30: Meet the Expert (MTE18) (Ticketed Session: €35,00)

Track: SCLC/Neuroendocrine Tumors

Room: Lehar 1-2

- **Perspectives in the Systemic Treatment of Small-Cell Lung Cancer**
Mary O'Brien, UK & Pieter Postmus, UK

07:30 - 08:30: Meet the Expert (MTE19) (Ticketed Session: €35,00)

Track: Chemotherapy/Targeted Therapy/Immunotherapy | Trial Design/Statistics

Room: Stolz 1

- **Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice**
Richard Gralla, USA & Kostas Syrigos, Greece

07:30 - 08:30: Meet the Expert (MTE20) (Ticketed Session: €35,00)

Track: Radiotherapy

Room: Stolz 2

- **Radiotherapy of Locally Advance NCSLC: Selecting the Right Patient for the Right Radiotherapy**
Dirk De Ruyscher, The Netherlands

07:30 - 08:30: Industry Supported Symposium: ISS Targeted Therapy on the Horizon for SCLC - AbbVie

Room: Lehar 3-4

Chair: Martin Reck, Germany

- 07:30 - **Challenges in SCLC Across Decades**
Martin Reck, Germany
- 07:40 - **Advancing the Study in SCLC - What is the Underlying Biology?**
Jean-Charles Soria, France
- 07:55 - **Emerging Novel Agents - A New Day for SCLC Treatment**
Ramaswamy Govindan, USA
- 08:15 - **Panel Discussion: Looking Over the Horizon - Future Treatment of SCLC**
All Faculty
- 08:25 - **Question & Answer**
All Faculty

08:35 - 10:25: Plenary Session (PL03): Presidential Symposium

Room: Hall D (Plenary Hall)

Chairs: David Carbone, USA & Robert Pirker, Austria

- 08:35 - **PL03.01: Presidential Address**
David Carbone, USA
- 08:45 - **PL03.02: Lung Cancer Staging - Changing the Clinical Practice**
Ramon Rami-Porta, Spain
- 09:05 - **PL03.03: Randomised Phase III Study of Osimertinib vs Platinum-Pemetrexed for EGFR T790M-Positive Advanced NSCLC (AURA3)**
Vassiliki Papadimitrakopoulou, USA
- 09:15 - **PL03.04: Discussant**
Tetsuya Mitsudomi, Japan
- 09:25 - **PL03.05: BRAIN: A Phase III Trial Comparing WBI and Chemotherapy with Icotinib in NSCLC with Brain Metastases Harboring EGFR Mutations (CTONG 1201)**
Yi Long Wu, China
- 09:35 - **PL03.06: Discussant:**
Jacek Jassem, Poland
- 09:45 - **PL03.07: First-line Ceritinib Versus Chemotherapy in Patients With ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)**
Gilberto De Castro Jr, Brazil
- 09:55 - **PL03.08: Discussant:**
Fiona Blackhall, UK
- 10:05 - **PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non-Small Cell Lung Cancer (GALAXY-2)**
Rathi Pillai, USA
- 10:15 - **PL03.10: Discussant:**
David Gandara, USA

10:30 - 11:00: Poster Session

Room: Hall B (Poster Area)

10:30: Press Conference (PR03)

Room: Schubert 1

11:00 - 12:30: Educational Session (ED07): Classification and Druggable Targets of Thoracic Tumors

Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy

Room: C1

Chairs: Adi Gazdar, USA & Helmut Popper, Austria

- 11:00 - **Adenocarcinomas and Squamous Cell Carcinomas**
William Travis, USA
- 11:20 - **The 2015 WHO Classification of Neuroendocrine Tumors**
Elisabeth Brambilla, France
- 11:40 - **The 2015 WHO Classification of Tumors of the Pleura**
Richard Attanoos, UK
- 12:00 - **The WHO Classification of Thymomas and Thymic Carcinomas**
Alexander Marx, Germany
- 12:20 - **Q&A**

11:00 - 12:30: Science Session (SC13): Interaction of COPD and Lung Cancer - Consequences for Early Diagnosis and Management

Track: Radiology/Staging/Screening | Pulmonology

Room: Stolz 1

Chairs: Anne-Pascale Meert, Belgium & Konstantinos Zarogoulidis, Greece

- 11:00 - **Common Pathogenesis of COPD and Lung Cancer**
Kwun Fong, Australia
- 11:20 - **Increased Risk for Lung Cancer in COPD**
Stephen Lam, Canada
- 11:40 - **Limitation by COPD for Diagnostic Procedures**
Gyula Ostoros, Hungary
- 12:00 - **Limitations by COPD for Treatment**
Yoichi Nakanishi, Japan
- 12:20 - **Q&A**

11:00 - 12:30: Science Session (SC14): Immunotherapy of NSCLC

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: C2

Chairs: Naiyer Rizvi, USA & Christoph Zielinski, Austria

- 11:00 - **Immunotherapy in the First-Line Setting of Advanced NSCLC**
Roy Herbst, USA
- 11:20 - **Immunotherapy in the Second-Line Setting of Advanced NSCLC**
Luis Paz-Ares, Spain
- 11:40 - **Combination Immunotherapy - Basic Considerations and First Outcomes**
David Spigel, USA
- 12:00 - **The CD47 Macrophage Checkpoint as a New Immunotherapy Target**
Branimir Sikic, USA
- 12:15 - **Tobacco Use and Immunotherapy**
Anne-Marie Dingemans, The Netherlands

11:00 - 12:30: Science Session (SC15): Clinical Trials: How to set Priorities?

Track: Trial Design/Statistics

Room: C8

Chairs: Rolf Stahel, Switzerland & Yi Long Wu, China

- 11:00 - **The American Perspective**
Suresh Ramalingam, USA
- 11:15 - **The European Perspective**
Rolf Stahel, Switzerland

- 11:30 - **The Chinese Perspective**
Yi Long Wu, China
- 11:45 - **The Japanese Perspective**
Yuichiro Ohe, Japan
- 12:00 - **The South American Perspective**
Gilbert Castro, Brazil
- 12:15 - **Q&A**

11:00 - 12:30: Interactive Session (IA05): The Practical use of the TNM Classifications for Thoracic Cancers

Track: Radiology/Staging/Screening

Room: C7

Chairs: Hisao Asamura, Japan & Christian Herold, Austria

- 11:00 - **Lung Cancer Cases**
Gustavo Lyons, Argentina
- 11:30 - **Mesothelioma Cases**
Mir Hoda, Austria
- 11:50 - **Thymic Carcinoma Cases**
Frank Detterbeck, USA
- 12:10 - **Esophageal Carcinoma Cases**
Thomas Rice, USA

11:00 - 12:30: Interactive Session (IA06): Staging* (Ticketed session: €35,00)

Group II (Space is limited to 20 participants)

Track: Radiology/Staging/Screening

Room: Schubert 3

Coordinators: Karin Dieckmann, Austria & Helmut Prosch, Austria

Trainers: Libor Havel, Czech Republic, Anna Kerpel-Fronius, Hungary & Elisabeth Stiefsohn, Austria

**Please note that this session is a duplicate of the session on Monday*

11:00 - 12:30: Nurses Session (NU03): Supporting Patients Receiving Treatment

Track: Nurses

Room: Schubert 5

Chairs: Vanessa Beattie, UK & Mary Duffy, Australia

- 11:00 - **Supporting Patients Undergoing Radical Treatments EPD - MARS Study**
Angela Tod, UK
- 11:20 - **Supporting Service Men & Women Receiving Treatment for Lung Cancer**
Naomi Hullinger, USA
- 11:40 - **eHealth and Remote Patient Monitoring and Supportive Care in Thoracic Oncology**
Roma Maguire, UK
- 12:00 - **Supportive Care in Patients Receiving Systemic Therapy**
Tanja Čufer, Slovenia
- 12:20 - **Q&A**

11:00 - 12:30: Patient Advocacy Session (PA03): Patient Support and Involvement in Research

Track: Patient Support and Advocacy Groups

Room: Schubert 6

Chairs: Jennifer King, USA & Pawel Muszumanski, Poland

- 11:00 - **Central European Lung Cancer Patient Network (CELCAPANET)**
Franz Buchberger, Austria
- 11:15 - **Psycho-Social and Communication Needs of Cancer Patients: Romanian Results**
Csaba László Dégi, Romania
- 11:30 - **How to Live with Lung Cancer? The Slovenian Lung Cancer Patient Support**
Andreja Škufca Smrdel, Slovenia
- 11:45 - **Patient Involvement in the Evaluation of Cancer Medicines: The EMA Experience**
Nathalie Bere, UK

11:00 - 12:30: Concurrent Abstract Sessions

11:00 - 12:30: Oral Session (OA09): Locally Advanced NSCLC: Innovative Treatment Strategies

Room: Strauss 3

Chairs: Walter Curran, USA & Myung-Ju Ahn, South Korea

- 11:00 - **OA09.01: The Number or the Position is the Main Prognostic Factor for N2 NSCLC? A Validation of New IASLC N Staging Proposal**
Sara Ricciardi, Italy
- 11:10 - **OA09.02: Should Surgery Be Part of the Multimodality Treatment for Stage IIIB Non-Small Cell Lung Cancer**
Stephane Collaud, France
- 11:20 - **OA09.03: Randomized Controlled Study Comparing Adjuvant versus Neo-Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC**
Yi Long Wu, China
- 11:30 - **OA09.04: Discussant:**
Masahiro Tsuboi, Japan
- 11:45 - **OA09.05: Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (FAZA) to Assess Tumor Hypoxia in Non-Small Cell Lung Cancer (NSCLC)**
Alexander Sun, Canada
- 11:55 - **OA09.06: Metformin Use during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)**
Krista Wink, Netherlands
- 12:05 - **OA09.07: Individual Isotoxic RT Dose Escalation Based on V20 and Advanced Technologies Benefit Stage III NSCLC Treated with CCRT**
Baosheng Li, China
- 12:15 - **OA09.08: Discussant:**
Paul van Houtte, Belgium

11:00 - 12:30: Oral Session (OA10): EGFR Mutations

Room: Strauss 1

Chairs: James Spicer, UK & Terufumi Kato, Japan

- 11:00 - **OA10.01: Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade**
Jonathan Riess, USA
- 11:10 - **OA10.02: Association of Variations in HLA-Class II and Other Loci with Susceptibility to EGFR-Mutated Lung Adenocarcinoma**
Takashi Kohno, Japan
- 11:20 - **OA10.03: YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer**
Rafael Rosell, Spain

- 11:30 - **OA10.04: Discussant:**
Hossein Borghaei, USA
- 11:45 - **OA10.05: EGFR Gene Mutations Affect Tumor-Infiltrating Stromal Cell Components in Early-Stage Lung Adenocarcinoma**
Toshiyuki Shima, Japan
- 11:55 - **OA10.06: Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study)**
Julien Mazieres, France
- 12:05 - **OA10.07: Report on Liquid Biopsies from Advanced Lung Adenocarcinoma Patients and Correlation with Their Tumor Biopsy Profiles**
Edgardo Santos, USA
- 12:15 - **OA10.08: Discussant:**
Frederico Cappuzzo, Italy

11:00 - 12:30: Oral Session (OA11): Angiogenesis in Advanced Lung Cancer

Room: Stolz 2

Chairs: Luis Montuenga, Spain & John Heymach, USA

- 11:00 - **OA11.01: Prolonged OS of Patients Exposed to Weekly Paclitaxel and Bevacizumab: Impact of the Cross-Over in the IFCT-1103 ULTIMATE Study**
Alexis Cortot, France
- 11:10 - **OA11.02: Randomized Phase 1b/3 Study of Erlotinib plus Ramucirumab in First-Line EGFR Mut + Stage IV NSCLC: Phase 1b Safety Results**
Kazuhiko Nakagawa, Japan
- 11:20 - **OA11.03: A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer**
Shun Lu, China
- 11:30 - **OA11.04: Discussant:**
Maurice Perol, France
- 11:45 - **OA11.05: A Phase 2 Study of Cabozantinib for Patients with Advanced RET-Rearranged Lung Cancers**
Alexander Drilon, USA
- 11:55 - **OA11.06: Role of Fibroblasts in the Subtype-Specific Therapeutic Effects of Nintedanib in Non-Small Cell Lung Cancer (NSCLC)**
Jordi Alcaraz, Spain
- 12:05 - **OA11.07: Combining Anti-Angiogenesis and Immunotherapy Enhances Antitumor Effect by Promoting Immune Response in Lung Cancer**
Sha Zhao, China
- 12:15 - **OA11.08: Discussant:**
Rainer Wiewrodt, Germany

11:00 - 12:30: Oral Session (OA12): SBRT and Other Issues in Early Stage NSCLC

Room: Strauss 2

Chairs: Dirk De Ruyscher, The Netherlands & Michael Rolf Mueller, Austria

- 11:00 - **OA12.01: Phase II Randomized Study of 2 SBRT Regimens for Medically Inoperable Patients with Node Negative Peripheral NSCLC**
Jorge A. Gomez Suescun, USA
- 11:10 - **OA12.02: Excellent Survival Achieved by Stereotactic Body Radiotherapy for Medically Operable and Young (< 75 Years) Patients with Stage I Lung Cancer**
Hiroshi Onishi, Japan

- 11:20 - **OA12.03: Percutaneous Cryoablation for Lung Cancer Patients for Whom Surgery or Radiotherapy is Contraindicated Due to Idiopathic Pulmonary Fibrosis**
Takashi Ohtsuka, Japan
- 11:30 - **OA12.04: Discussant:**
Matthias Guckenberger, Switzerland
- 11:45 - **OA12.05: Noninvasive CT-Based Image Biopsy System (iBiopsy) for Early Stage Lung Adenocarcinoma**
Dawei Yang, China
- 11:55 - **OA12.06: A Retrospective Analysis of Patients with Small Lung Adenocarcinoma (≤ 2 cm) by New World Health Organization Classification**
Keita Nakao, Japan
- 12:05 - **OA12.07: Selection for Adjuvant Chemotherapy in Stage IB Non-Small Cell Lung Cancer: A Propensity Score-Matched Analysis**
Jae Hyun Jeon, South Korea
- 12:15 - **OA12.08: Discussant:**
Ryuichi Waseda, Japan

11:00 - 12:30: Mini Oral Session (MA07): ALK-ROS1 in Advanced NSCLC

Room: Lehar 1-2

Chairs: Navneet Singh, India & Jürgen Wolf, Germany

- 11:00 - **MA07.01: Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC**
Sai-Hong Ignatius Ou, USA
- 11:06 - **MA07.02: Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer**
Shirish Gadgeel, USA
- 11:12 - **MA07.03: Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)**
Young Kim, Japan
- 11:18 - **MA07.04: Discussant:**
Robert Doebele, USA
- 11:30 - **MA07.05: EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results**
Sebastian Michels, Germany
- 11:36 - **MA07.06: Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Preliminary Results of the METROS Trial**
Lorenza Landi, Italy
- 11:42 - **MA07.07: Ceritinib in ROS1-Rearranged Non-Small-Cell Lung Cancer: An Update of Korean Nationwide Phase II Study**
Byoung Chul Cho, South Korea
- 11:48 - **MA07.08: Discussant:**
Enriqueta Felip, Spain
- 12:00 - **MA07.09: Mass Spectrometry Profiling and Imaging Platform for Novel Precision Drug Resistance Biomarkers Discovery in EML4-ALK Lung Adenocarcinoma**
Patrick Ma, USA
- 12:06 - **MA07.10: HDAC Inhibition Overcomes Crizotinib-Resistance by Mesenchymal-Epithelial Transition (MET) in EML4-ALK Lung Cancer Cells**
Koji Fukuda, Japan
- 12:12 - **MA07.11: Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+ Non-Small-Cell Lung Cancer (NSCLC)**

E Felip, Spain

- 12:18 - **MA07.12: Discussant:**
Benjamin Besse, France

11:00 - 12:30: Mini Oral Session (MA08): Treatment Monitoring in Advanced NSCLC

Room: Lehar 3-4

Chairs: Roman Perez-Soler, USA & Thanyanan Reungwetwattana, Thailand

- 11:00 - **MA08.01: A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma**
Heather Wakelee, USA
- 11:06 - **MA08.02: Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315**
Frank Griesinger, Germany
- 11:12 - **MA08.03: Osimertinib vs Platinum-Pemetrexed for T790M-Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis**
Yi Long Wu, China
- 11:18 - **MA08.04: Discussant:**
Baohui Han, China
- 11:30 - **MA08.05: Depth of Response to First-Line EGFR TKI Does Not Predict Survival in EGFR-Mutated NSCLC Patients**
Ting-Hui Wu, Taiwan
- 11:36 - **MA08.06: Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy**
Daniel Morgensztern, USA
- 11:42 - **MA08.07: Prospective Sequential Counts of Total CTC or cKIT+CTC in Advanced NSCLC with 1st Line Chemotherapy (POLICE)**
Yi Long Wu, China
- 11:48 - **MA08.08: Discussant:**
Aaron Mansfield, USA
- 12:00 - **MA08.09: Monitoring Plasma EGFR Mutations during First Line Treatment with EGFR TKIs in NSCLC Patients**
Katja Mohorcic, Slovenia
- 12:06 - **MA08.10: Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR)**
Koichi Azuma, Japan
- 12:12 - **MA08.11: Monitoring the Emergence of EGFR T790M ctDNA in Urine from EGFR Mutated NSCLC Patients to Predict Response to 3rd Generation Anti-EGFR TKIs**
Hatim Husain, USA
- 12:18 - **MA08.12: Discussant:**
Martin Filipits, Austria

12:45 - 14:15: Industry Supported Symposium: ISS Novel Treatment Strategies for ALK+ NSCLC: From Evidence to Practice - Novartis

Room: Lehar 3-4

Chair: Solange Peters, Switzerland

- 12:45 - **Welcome & Introduction**
Solange Peters, Switzerland
- 12:50 - **ALK+ NSCLC: not your Typical Patients**
Heather Wakelee, USA

- 13:05 - **Optimizing Outcomes for your ALK+ NSCLC Patients**
Fabrice Barlesi, France
- 13:20 - **The Future of ALK+ NSCLC Treatment and What this Implies for Your Clinical Practice**
Daniel Shao-Weng Tan, Singapore
- 13:40 - **Panel Discussion: Challenges in Sequencing Therapy for your ALK+ NSCLC Patients**
All Faculty
- 14:10 - **Conclusion and Close**
Solange Peters, Switzerland

14:15 - 15:45: Concurrent Abstract Sessions

14:15 - 15:45: Oral Session (OA13): Immunotherapy in Malignant Pleural Mesothelioma: Current Status of Trials and New Approaches

Room: Stolz 1

Chairs: Raffit Hassan, USA & Paul Baas, The Netherlands

- 14:15 - **OA13.01: A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies**
Paul Baas, Netherlands
- 14:25 - **OA13.02: Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis**
Hedy Kindler, USA
- 14:35 - **OA13.03: Long-Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE-028**
Evan Alley, USA
- 14:45 - **OA13.04: Discussant:**
Cornelius Waller, Germany
- 15:00 - **OA13.05: Somatic Genetic Alterations and Immune Microenvironment in Malignant Pleural Mesothelioma**
Wickii Vigneswaran, USA
- 15:10 - **OA13.06: Autologous Dendritic Cells Loaded with Allogeneic Tumor Cell Lysate (Pheralys®) in Patients with Mesothelioma: Final Results of a Phase I Study**
Joachim Aerts, Netherlands
- 15:20 - **OA13.07: Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma**
Tobias Peikert, USA
- 15:30 - **OA13.08: Discussant:**
Anna Nowak, Australia

14:15 - 15:45: Mini Oral Session (MA09) Immunotherapy Combinations

Room: Strauss 2

Chairs: Edward Garon, USA & Martin Sebastian, Germany

- 14:15 - **MA09.01: Dual Blockade of PD-1 and C5a/C5aR Synergistically Protects against Non-Small Cell Lung Cancer Tumor Growth**
Ruben Pio, Spain
- 14:21 - **MA09.02: Pembrolizumab + Carboplatin and Pemetrexed as 1st-Line Therapy for Advanced Non-Small Cell Lung Cancer: KEYNOTE-021 Cohort G**
Corey Langer, USA



- 14:27 - **MA09.03: Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226**
Rosalyn Juergens, Canada
- 14:33 - **MA09.04: Discussant:**
David Planchard, France
- 14:45 - **MA09.05: Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial**
Matthew Hellmann, USA
- 14:51 - **MA09.06: Viagenpumatucl-L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial**
Daniel Morgensztern, USA
- 14:57 - **MA09.07: Phase I Trial of in situ Vaccination with CCL21 Gene-Modified DC Induces Specific Systemic Immune Response and Tumor Infiltrating CD8+ T Cells**
Steven Dubinett, USA
- 15:03 - **MA09.08: Discussant:**
Luboš Petruželka, Czech Republic
- 15:15 - **MA09.09: First-In-Human Phase 1 Study of ABBV-399, an Antibody-Drug Conjugate (ADC) Targeting C-Met, in Patients with Non-Small Cell Lung Cancer (NSCLC)**
Eric Angevin, France
- 15:21 - **MA09.10: A NaPi2b Antibody-Drug Conjugate Induces Durable Complete Tumor Regressions in Patient-Derived Xenograft Models of NSCLC**
Donald Bergstrom, USA
- 15:27 - **MA09.11: Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)**
Benjamin Besse, France
- 15:33 - **MA09.12: Discussant:**
TBD

14:15 - 15:45: Mini Oral Session (MA10): Facing the Real World: New Staging System and Response Evaluation in Immunotherapy

Room: Stolz 2

Chairs: Paris Kosmidis, Greece & Miroslaw Kozlowski, Poland

- 14:15 - **MA10.01: Validations of the 8th AJCC/UICC Lung Cancer Staging System in a Large North America Cohort**
Lin Yang, China
- 14:21 - **MA10.02: Clinical Staging in the 8th Edition TNM for Lung Cancer is Inaccurate**
Aleksander Mani, UK
- 14:27 - **MA10.03: Investigating the Potential Utility of the Alternative 9th Edition IASLC Nodal Staging Classification in NSCLC**
Haval Balata, UK
- 14:33 - **MA10.04: Discussant:**
Raymond Osarogiagbon, USA
- 14:45 - **MA10.05: Proposals for the Novel Clinical T Categories Based on the Presence of Ground Glass Opacity Component in Lung Adenocarcinoma**
Aritoshi Hattori, Japan
- 14:51 - **MA10.06: Centrality Definition in Non Small Cell Lung Cancer. Predictor For Occult Mediastinal Lymph Node Involvement**
David Sanchez-Lorente, Spain
- 14:57 - **MA10.07: 18F-Fluorodeoxyglucose Positron Emission Tomography Scan in Solid-Type Stage-I Pulmonary Adenocarcinomas: What Cause False-Negative Cases?**

- Tommaso Ricchetti, Italy
- 15:03 - **MA10.08: Discussant:** TBD
 - 15:15 - **MA10.09: Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check-Point Inhibitors Response**
Giovanni Rossi, Italy
 - 15:21 - **MA10.10: [18F]-FDG-PET/CT Early Response to Nivolumab in NSCLC**
Alexis Cortot, France
 - 15:27 - **MA10.11: Comparison among Different Radiological Criteria for Assessing Response to Nivolumab in Advanced Non-Small Cell Lung Cancer**
Francesco Grossi, Italy
 - 15:33 - **MA10.12: Discussant:**
Prasanta R. Mohapatra, India

14:15 - 15:45: Mini Oral Session (MA11): Novel Approaches in SCLC and Neuroendocrine Tumors

Room: Strauss 3

Chairs: Primo Lara, USA & Andrea Mohn-Staudner, Austria

- 14:15 - **MA11.01: Molecular Profiling of Large Cell Neuroendocrine Carcinoma Using Capture-Based Targeted Sequencing**
Zhen Zhou, China
- 14:21 - **MA11.02: Mutational Burden in Pulmonary Neuroendocrine Tumors (puNETs)**
Ivana Sullivan, France
- 14:27 - **MA11.03: INSM1 is a Novel Biomarker and a Crucial Regulator of the Neuroendocrine Differentiation Pathway in Neuroendocrine Tumours of the Lung**
Fujino Kosuke, Canada
- 14:33 - **MA11.03: Discussant:**
TBD
- 14:45 - **MA11.05: A Case-Control Study to Test the Use of ctDNA in the Early Detection of SCLC Reveals TP53 Mutations in Non-Cancer Controls**
Lynnette Fernandez-Cuesta, France
- 14:51 - **MA11.06: SWOG 0124: Platinum-Sensitivity Status and Post-Progression Survival in Patients with Extensive-Stage Small Cell Lung Cancer**
Primo Lara, USA
- 14:57 - **MA11.07: Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial**
Lauren Averett Byers, USA
- 15:03 - **MA11.08: Discussant:**
Andrea Ardizzoni, Italy
- 15:15 - **MA11.09: Progastrin-Releasing Peptide (ProGRP) to Rule out Progressive Disease in Patients with Small Cell Lung Carcinoma (SCLC)**
Xiaotong Zhang, China
- 15:21 - **MA11.10: Prospective Study of Genome-Wide Strexome and Transcriptome Profiling in Patients with Small Cell Lung Cancer Progressing after 1st Line Therapy**
Glen Weiss, USA
- 15:27 - **MA11.11: Is Hippocampal Avoidance during Whole Brain Radiotherapy Risky for Small Cell Lung Cancer Patients?**
Esra Kirakli, Turkey
- 15:33 - **MA11.12: Discussant:**
Hideo Kunitoh, Japan

14:15 - 15:45: Mini Oral Session (MA12): Miscellaneous Biology/Pathology

Room: Schubert 1

Chairs: Balazs Dome, Austria & TBD

- 14:15 - **MA12.01: Next Generation Sequencing Based Clinical Framework for Analyses of Treatment Predictive Mutations and Gene Fusions in Lung Cancer**
Anna Karlsson, Sweden
- 14:21 - **MA12.02: MMP12 and LMO7, Two Key Players on opposite Sides of Early Lung Squamous Cell Carcinoma Development**
Angela Barrett, UK
- 14:27 - **MA12.03: Discussant:**
Elisabeth Brambilla, France
- 14:39 - **MA12.04: Mitochondrial-Related Proteins, PGAM5 and FUNDC1, in COPD-Associated Non-Small Cell Lung Carcinoma**
Francois Kwong, UK
- 14:45 - **MA12.05: Can Tumor Spread through Air Spaces (STAS) in Lung Adenocarcinomas Be Predicted Pre- and Intraoperatively?**
Koji Kameda, USA
- 14:51 - **MA12.06: Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis**
Shaohua Lu, USA
- 14:51 - **MA12.07: Discussant:**
Erik Thunnissen, The Netherlands
- 14:57 - **MA12.08: Clinicopathological Significance of Increasing Percentage of High-Grade Histological Subtypes in Lung Adenocarcinomas**
Shaohua Lu, USA
- 15:15 - **MA12.09: Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact**
Takashi Eguchi, USA
- 15:21 - **MA12.10: Histological Subtyping of Matched Primary and Metastases Sites in Lung Adenocarcinoma: Significance of Solid Predominance**
Yusuke Takahashi, USA
- 15:27 - **MA12.11: Discussant:**
Wendy Cooper, Australia

14:30 - 15:45: Educational Session (ED08): Early-Stage NSCLC: State-of-the-Art Treatment and Perspectives

Track: Early Stage NSCLC

Room: C2

Chairs: Thierry Le Chevalier, France & Masahiro Tsuboi, Japan

- 14:30 - **Surgery of Early-Stage NSCLC**
Michael Rolf Mueller, Austria
- 14:50 - **The Role of Radiotherapy in Early-Stage NSCLC**
Suresh Senan, The Netherlands
- 15:10 - **Adjuvant Chemotherapy of Completely Resected**
Glennwood Goss, Canada
- 15:30 - **Perspectives of Targeted Therapies and Immunotherapy in Completely Resected NSCLC**
Heather Wakelee, USA

14:30 - 15:45: Educational Session (ED09): Advances in Lung Cancer Screening

Track: Radiology/Staging/Screening

Room: C8

Chairs: Christine Berg, USA & Rudolf Huber, Germany

- 14:30 - **Radiological Advances in Lung Cancer Screening**
Mathias Prokop, The Netherlands
- 14:50 - **Risk Prediction Modelling in Lung Cancer Screening Programs**
Martin Tammemägi, Canada
- 15:10 - **Overdiagnosis in Lung Cancer Screening**
Charles Powell, USA
- 15:30 - **Cost Effectiveness of CT Screening**
Bruce Pyenson, USA

14:30 - 15:45: Pro-Con Session (PC02): By 2030 Chemotherapy will Remain Standard of Care for the Majority of Patients with NSCLC Stages I-IV

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: Hall C7

Chairs: Enriqueta Felip, Spain & Benjamin Besse, France

- 14:30 - **Introduction & Vote**
Benjamin Besse, France
- 14:45 - **Pro Chemotherapy**
Nasser Hanna, USA
- 15:05 - **Contra Chemotherapy**
Karen Kelly, USA
- 15:25 - **Discussion & Vote**
Enriqueta Felip, Spain

14:30 - 15:45: Science Session (SC16): Superior Sulcus Tumors

Track: Locally Advanced NSCLC | Early Stage NSCLC | Radiology/Staging/Screening

Room: Lehar 1-2

Chairs: David Jones, USA & Walter Klepetko, Austria

- 14:30 - **Imaging Techniques for Staging and Restaging of Superior Sulcus Tumors**
Helmut Prosch, Austria
- 14:50 - **Surgical Approaches in Superior Sulcus Tumors**
Dominique Grunenwald, France
- 15:10 - **Radiotherapy for Sulcus Superior Tumors**
Maria Werner-Wasik, USA
- 15:30 - **Individualized Extended Lung Cancer Surgery: The Chinese Experience**
Qinghua Zhou, China

14:30 - 15:45: Science Session (SC17): Lung Cancer: A Global Cancer with Different Regional Challenges

Track: Regional Aspects/Health Policy/Public Health

Room: Strauss 1

Chairs: Carlos Vallejos, Peru & TBD

- 14:30 - **Lung Cancer in Russia: Challenges and Perspectives**
Vera Gorbunova, Russia
- 14:45 - **Lung Cancer in China: Challenges and Perspectives**

Li Zhang, China

- 15:00 - **Lung Cancer in India: Challenges and Perspectives**
Digambar Behera, India
- 15:15 - **Lung Cancer in Latin America: Challenges and Perspectives**
Eduardo Richardet, Argentina
- 15:30 - **Lung Cancer in Africa: Challenges and Perspectives**
Rabab Gaafar, Egypt

14:30 - 15:45: Nurses Session (NU04): Managing Toxicity

Track: Nurses

Room: Schubert 5

Chairs: Mary Hesdorffer, USA & Marianne Davies, USA

- 14:30 - **Management of Toxicities Associated with Immunotherapy in the Lung Cancer Patients**
Michelle Turner, USA
- 14:50 - **Experience of Lung Cancer Patients Receiving Immunotherapy**
Rachel Thomas, UK
- 15:10 - **Where are we With TKI Toxicities**
Beth Eaby-Sandy, USA
- 15:30- **Q&A**

14:30 - 15:45: Patient Advocacy Session (PA04): FOCUS ON ADVOCACY AND COMMUNICATION: Joint IASLC/ Global Lung Cancer Coalition Session (GLCC)

Track: Patient Support and Advocacy Groups

Room: Schubert 6

Chairs: Aoife McNamara, Ireland & Andreja Šajnić, Croatia

- 14:30 - **A Realistic Goal? Achieving a Tobacco Free Ireland by 2025**
Donal Buggy, Ireland
- 14:45 - **The Global State of Lung Cancer Research - Communicating the Messages**
Sarah Winstone, UK
- 15:05 - **Helpline: Adapting to Changing Needs and Evolving Science**
Jennifer King, USA
- 15:25 - **How it Feels Campaign: The Impact of a Large General Public Campaign**
Kay Bayne, USA

14:30 - 15:00: IASLC Business Meeting

Room: Schubert 2

14:30 - 15:45: Poster Session with Presenters Present (P2)

Room: Hall B (Poster Area)

- [Click here for the 17th IASLC WCLC Poster Program >>](#)

16:00 - 17:30: Educational Session (ED10): Locally Advanced NSCLC: State-of-the-Art Treatment

Track: Locally Advanced NSCLC

Room: C1

Chairs: Wilfried Eberhardt, Germany & Kenji Suzuki, Japan

- 16:00 - **Chemoradiotherapy of Stage III NSCLC**

- Francoise Mornex, France
- 16:25 - **The Role of Surgery in Stage III NSCLC**
Walter Klepetko, Austria
 - 16:45 - **New Developments in Radiotherapy of Stage III NSCLC**
Jacek Jassem, Poland
 - 17:05 - **New Developments for Systemic Therapies in Stage III NSCLC**
Everett Vokes, USA
 - 17:25 - **Q&A**

16:00 - 17:30: Science Session (SC18): Precision Screening for Lung Cancer

Room: Lehar 1-2

Track: Radiology/Staging/Screening

Chairs: Andrew Nicholson, UK & Gyula Ostoros, Hungary

- 16:00 - **Field Cancerization in the Airways and its Application to Lung Cancer Early Detection**
Ignacio Wistuba, USA
- 16:20 - **Integrating Lung Cancer Biomarkers into Future Screening Programs**
Pierre Massion, USA
- 16:40 - **Lung Cancer Screening, COPD and Cardiovascular Diseases**
Rudolf Huber, Germany
- 17:00 - **Exhaled Biomarker Fingerprints for Early Detection**
Ildiko Horvath, Hungary
- 17:15 - **UK Lung Screening Trial Cost Effectiveness and Current Planning Status of International Lung Cancer Screening Programs**
John Field, UK

16:00 - 17:30: Science Session (SC19): Interventional Pulmonology in Diagnosis and Treatment of Thoracic Malignancies

Track: Pulmonology | Surgery

Room: Lehar 3-4

Chairs: Yoichi Nakanishi, Japan & Ruxandra Ulmeanu, Romania

- 16:00 - **Diagnosis of Lung Cancer: Multimodal Devices for Peripheral Pulmonary Lesions**
Noriaki Kurimoto, Japan
- 16:20 - **Invasive Staging of Lung Cancer: EBUS, EUS and Beyond**
Kazuhiro Yasufuku, Canada
- 16:40 - **Medical Thoracoscopy**
Ales Rozman, Slovenia
- 17:00 - 17:20: **Endobronchial Palliation in Thoracic Malignancies**
Zsolt Pápai-Székely, Hungary

16:00 - 17:30: Science Session (SC20): Small is Beautiful: Impact of Surgical Approach

Track: Surgery

Room: Strauss 1

Chairs: Alan Sihoe, Hong Kong & Alper Toker, Turkey

- 16:00 - **Muscle-Sparing Thoracotomy: Can it Still be Considered a Standard?**
Clemens Aigner, Germany
- 16:20 - **What Have we Achieved? Should it be Performed for Stages Higher than Stage I Disease?**



- Tomasz Grodzki, Poland
- 16:40 - **Robotic Surgery: What can be Done?**
Franca Melfi, Italy
- 17:00 - **Uniportal VATS**
Diego Gonzalez Rivas, Spain
- 17:20 - **Q&A**

16:00 - 17:30: Science Session (SC21): Predictive Biomarkers for Outcome of Systemic Therapy in NSCLC

Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy

Room: C7

Chairs: Keith Kerr, UK & Tetsuya Mitsudomi, Japan

- 16:00 - **Predictive Biomarkers in NSCLC: The Impact of Tumor Heterogeneity**
Yasushi Yatabe, Japan
- 16:20 - **Predictive Biomarkers for Chemotherapy of NSCLC**
Martin Filipits, Austria
- 16:40 - **Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer**
Fred Hirsch, USA
- 17:00 - **Patient-Derived Xenografts for Guiding Therapy of Lung Cancer**
Byoung Chul Cho, South Korea
- 17:15 - **Emerging Role of Liquid Biopsies in NSCLC**
Philipp Mack, USA

16:00 - 17:30: Science Session (SC22): Selection and Monitoring of Patients for Immune Checkpoint Inhibitors

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: C8

Chairs: Giorgio Scagliotti, Italy & Johan Vansteenkiste, Belgium

- 16:00 - **How do I Define Optimal Candidates for Immunotherapy in my Practice?**
Johan Vansteenkiste, Belgium
- 16:20 - **How do I Monitor for Efficacy?**
Naiyer Rizvi, USA
- 16:40 - **How do I Monitor for and Treat Immune-Related Events?**
Alexander Spira, USA
- 17:00 - **How can Immunotherapy be Implemented in a Cost-Effective Strategy?**
Christoph Zielinski, Austria
- 17:20 - **Q&A**

16:00 - 17:30: Science Session (SC23): The Importance of Co-Operative Groups

Track: Scientific Co-Operation/Research Groups

Room: Strauss 3

Chairs: Jaime de la Garza, Mexico & Jin Soo Lee, South Korea

- 16:00 - **Cooperative Groups in Latin America**
Clarissa Mathias, Brazil
- 16:15 - **Co-Operative Groups in Europe: Lessons Learned and Perspectives**
Solange Peters, Switzerland
- 16:30 - **How Could High-Volume Centers in Developing Countries Access Cooperative Group Trials?**

Ufuk Yilmaz, Turkey

- 16:45 - **Cooperative Groups in China: The CSCO Experience**
Qing Zhou, China
- 17:00 - **Co-Operative Groups in North America**
Shakun Malik, USA
- 17:15 - **Challenges and Costs of Cooperative Group Trials**
Thomas Brodowicz, Austria

16:00 - 17:30: Interactive Session (IA07): Target Delineation* (Ticketed Session: €35,00)

Track: Radiotherapy

Room: Schubert 3

Coordinators: Karin Dieckmann, Austria & Helmut Prosch, Austria

Group II (Space is limited to 20 participants)

Trainers: Corinne Faivre-Finn, UK, Laurie Gaspar, USA & Billy Loo, USA

**Please note that this session is a duplicate of the session on Monday*

16:00 - 17:30: Interactive Session (IA08) Tobacco & Youth

Track: Epidemiology/Tobacco Control and Cessation/Prevention

Room: C2

Chairs: Cornel Radu-Loghin, Romania & TBD

- **Tobacco Use in Low-Income Countries**
Nise Yamaguchi, Brazil
- **Tobacco use in Austrian Young People**
Daniela Jahn-Kuch, Austria
- **How Technology can Assist in Lung Cancer Prevention**
Alexander Prokhorov, USA
- **Tobacco Control Policies and Youth Smoking**
Florin Mihaltan, Romania

16:00 - 17:30: Concurrent Abstract Sessions

16:00 - 17:30: Oral Session (OA14): Nurses in Care for Lung Cancer and in Research

Room: Schubert 5

Chairs: Melissa Culligan, USA & Massey Nematollahi, Canada

- 16:00 - **OA14.01: Acceptability of an Advanced Practice Nurse in Lung Cancer by Health Professionals and Patients: A Qualitative Exploration**
Andrea Serena, Switzerland
- 16:10 - **OA14.02: Nursing and Allied Healthcare Practitioner Driven Initiative to Develop an Integrated Educational and Assessment Program for Immunotherapy**
Marianne Davies, USA
- 16:20 - **OA14.03: Integrating Therapies into a Specialist Lung Cancer Nursing Team: An Evaluation**
Carol Brimacombe, UK
- 16:10 - **OA14.04: Discussant:**
John McPhelim, UK
- 16:45 - **OA14.05: A Framework to Support the Lung Cancer Nurse Specialist in the Development and Evaluation of Nurse-Led Clinics**
Sharon Savory, UK

- 16:55 - **OA14.06: The Role of a Multi-Disciplinary Team Approach to Early Rehabilitation and Symptom Management in Thoracic Oncology**
Pippa Labuc, UK
- 17:05 - **OA14.07: The Relationship between Lung Cancer Stigma and Patient Reported Outcomes**
Liane Lewis, UK
- 17:15 - **OA14.08: Discussant:**
TBD

16:00 - 17:30: Oral Session (OA15): Sublobar Resections for Early Stage NSCLC

Room: Stolz 2

Chairs: Mir Hoda, Austria & David Waller, United Kingdom

- 16:00 - **OA15.01: Limited Resection Trial for Pulmonary Sub-solid Nodules: Case Selection Based on High Resolution CT: Outcome at Median Follow-up of 105 Months**
Junji Yoshida, Japan
- 16:10 - **OA15.02: Survival Outcomes in Sublobar Resection for Clinical T1N0M0 Non-Small Cell Lung Cancer: Wedge Resection or Segmentectomy**
Aki Kobayashi, Japan
- 16:20 - **OA15.03: Comparison of Prognosis between Lobectomy and Sublobar Resection for Clinical Stage I Non-Small Cell Lung Cancer with Interstitial Lung Disease**
Yasuhiro Tsutani, Japan
- 16:30 - **OA15.04: Discussant:**
Stefan Watzka, Austria
- 16:45 - **OA15.05: Anatomical Pulmonary Segmentectomy and Sub-Segmentectomy for Lung Cancer Using the Novel Fluorescence Technique with Vitamin B2**
Ryuichi Waseda, Japan
- 16:55 - **OA15.06: The Efficacy of Lung Volume Analyzer for Measuring Resection Margin in Pulmonary Segmentectomy for Malignant Diseases**
Yasuo Sekine, Japan
- 17:05 - **OA15.07: Is Necessary Completion Lobectomy in NSCLC (≤ 2 cm) with Visceral Pleural Invasion or Lymphovascular Invasion after Sublobar Resection?**
Youngkyu Moon, South Korea
- 17:15 - **OA15.08: Discussant:**
Wen-Zhao Zhong, China

16:00 - 17:30: Oral Session (OA16): Improving the Quality of Lung Cancer Care - Patients Perspective

Room: Schubert 6

Chairs: TBD

- 16:00 - **OA16.01: The Role of Patient Groups in Integrating the Patient Voice into Drug Funding Decisions**
Christina Sit, Canada
- 16:10 - **OA16.02: Shared Decision Making (SDM) and Patient Decision Aids (PDAs) in Lung Cancer: Survey of Patients, Significant Others or Caregivers**
Laurie Gaspar, USA
- 16:20 - **OA16.03: The ALCF Centers of Excellence Model Delivers a Standard of Care to the Community Similar to Academic and Research Centers**
Raymond Osarogiagbon, USA
- 16:30 - **OA16.04: Discussant:**

Joan Schiller, USA

- 16:45 - **OA16.05: Socioeconomic Determinants of Late Diagnosis of Lung Cancer in France: A Nationwide Study (the TERRITOIRE Study)**
Pierre Jean Souquet, France
- 16:55 - **OA16.06: Willingness for Multiple Biopsies to Improve Quality of Lung Cancer Care: Understanding the Patient Perspective**
Upal Basu Roy, USA
- 17:05 - **OA16.07: Patient-Driven Epidemiologic Assessment of ROS1-Fusion Driven Cancers**
Guneet Walia, USA
- 17:15 - **OA16.08: Discussant:**
Peter Berzinec, Slovakia

16:00 - 17:30: Oral Session (OA17): Aspects of Health Policies and Public Health

Room: Schubert 1

Chairs: Meinhard Kneussl, Austria & TBD

- 16:00 - **OA17.01: Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US**
Gilberto Lopes, Brazil
- 16:10 - **OA17.02: Potential Health and Economic Consequences of Organized vs Opportunistic Lung Cancer Screening in Canada**
William Evans, Canada
- 16:20 - **OA17.03: Insurance Type Influences Stage, Treatment, and Survival in Asian American Lung Cancer Patients**
Apichat Tantraworasin, USA
- 16:30 - **OA17.04: Discussant:**
Gilberto Lopes, Brazil
- 16:45 - **OA17.05: Survival in a Cohort of Patients with Lung Cancer: The Role of Age and Gender on Prognosis**
Juliana Franceschini, Brazil
- 16:55 - **OA17.06: Make the World Beautiful and Healthy by Making Your Country Smoke Free: Case Study between Iceland and Thailand?**
May Cho, Thailand
- 17:05 - **OA17.07: Time from the Identification of a Suspicious Pulmonary Lesion to the Treatment of Non-Small Cell Lung Cancer**
Claire Hiles, USA
- 17:15 - **OA17.08: Discussant:**
Govind Babu, India

16:00 - 17:30: Mini Oral Session (MA13): Modern Technologies and Biological Factors in Radiotherapy

Room: Stolz 1

Chairs: Michael Thomas, Germany & Paul Mitchell, Australia

- 16:00 - **MA13.01: Markerless Tumour Tracking during Lung Radiotherapy Using Intrafraction X-Ray Imaging**
Chun-Chien (Andy) Shieh, Australia
- 16:06 - **MA13.02: First-In-Human Clinical Experience with Real-Time Tumor Targeting via MLC Tracking for Stereotactic Radiotherapy of Lung Cancer**
Jeremy Booth, Australia

- 16:12 - **MA13.03: Analysis of Intra-Thoracic Anatomical Changes Observed in Clinical Workflow of Cone-Beam CT Guided Radiotherapy for Lung Cancer**
José Belderbos, Netherlands
- 16:18 - **MA13.04: Discussant:**
Christoph Pöttgen, Germany
- 16:30 - **MA13.05: Nivolumab in Non-Small Cell Lung Cancer (NSCLC): The Real-Life Data**
Elizabeth Dudnik, Israel
- 16:36 - **MA13.06: Integrative Genomic Profiling Identifies BRAF Mutations as Novel Radiotherapeutic Targets in Adenocarcinomas of the Lung**
Mohamed Abazeed, USA
- 16:42 - **MA13.07: Tumor-Targeted Radiation Promotes Abscopal Efficacy of Regionally Administered CAR T Cells: A Rationale for Clinical Trial**
Masha Zeltsman, USA
- 16:48 - **MA13.08: Discussant:**
Miklos Pless, Switzerland
- 17:00 - **MA13.09: Serial FDG and FLT PET/CT during Curative-Intent Chemo-Radiotherapy for NSCLC Impacts Patient Management and May Predict Clinical Outcomes**
David Ball, Australia
- 17:06 - **MA13.10: Magnetic Resonance Imaging-Guided Delivery of Lung Stereotactic Radiotherapy Using Patient-Controlled Visual Guidance**
Shyama Tetar, Netherlands
- 17:12 - **MA13.11: Investigating the Feasibility of Establishing a Prospective Cohort of Lung Cancer Patients Following Radiotherapy with Curative Intent**
Lynn Calman, UK
- 17:18 - **MA13.12: Discussant:**
Antonio Juretic, Croatia

16:00 - 17:30: Mini Oral Session (MA14): Immunotherapy in Advanced NSCLC: Biomarkers and Costs
Room: Strauss 2

Chairs: Martin Reck, Germany & David Spigel, USA

- 16:00 - **MA14.01: Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC)**
Siraj Ali, USA
- 16:06 - **MA14.02: Evaluation of PD1/PDL1 Expression on Peripheral Blood Cells Subpopulations in Patients with Non-Small Cell Lung Cancer**
Oscar Arrieta, Mexico
- 16:12 - **MA14.03: The Impact of Genomic Landscape of EGFR Mutant NSCLC on Response to Targeted and Immune Therapy**
Yasir Elamin, USA
- 16:18 - **MA14.04: Discussant:**
Marcin Moniuszko, Poland
- 16:30 - **MA14.05: Implications of Implementation of a PD-L1 Biomarker-Based Strategy for Treatment of Advanced NSCLC**
Thomas Burke, USA
- 16:36 - **MA14.06: Nivolumab in Never Smoker Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)**
Giuseppe Lo Russo, Italy
- 16:42 - **MA14.07: Real Life Experience with Immunotherapy in the Netherlands**
Robert Schouten, Netherlands



- 16:48 - **MA14.08: Discussant:**
Luis Raez, USA
- 17:00 - **MA14.09: Demonstrating Life Expectancy Gains with Immuno-Oncology (IO) Therapies**
Robert Figlin, USA
- 17:06 - **MA14.10: Relative Impact of Disease Management Costs in the Economics of Pembrolizumab in Previously Treated PD-L1 Positive Advanced NSCLC**
Thomas Burke, USA
- 17:12 - **MA14.11: An Estimate of the Economic Impact of Immunotherapy Relative to PD-L1 Expression in Brazil - An Update with Brazilian Costs**
Gilberto Lopes, Brazil
- 17:18 - **MA14.12: Discussant:**
George Simon, USA

17:45 - 19:15: Industry Supported Symposium: ISS Harnessing the Power of Immunotherapy and Targeted Therapy: Translating Evidence into Practice - Roche

Room: C2

Chairs: David Spigel, USA

- 17:45 - **Welcome & Introduction**
David Spigel, USA
- 17:50 - **ALK: The Power of Targeted Therapy**
Frank Griesinger, Germany
- 18:15 - **Latest Developments in the Treatment of EGFR Mut+ NSCLC**
Federico Cappuzzo, Italy
- 18:30 - **The Power of the Immune System: Immunotherapy in Practice**
Achim Rittmeyer, Germany
- 19:10 - **Summary and Close**
David Spigel, USA

Wednesday, December 7, 2016**07:30 - 08:30: WCLC 2016 Scientific Highlights (SH05)**

Tracks: 07. Advanced NSCLC

12. Chemotherapy/Targeted Therapy/Immunotherapy

Room: Hall C1

Chairs: TBD

- **Chemotherapy of Advanced NSCLC:**
Chandra Belani, USA
- **Targeted Therapy of Advanced NSCLC:**
James Spicer, UK
- **Immunotherapy of Advanced NSCLC:**
Lucio Crino, Italy

07:30 - 08:30: WCLC 2016 Scientific Highlights (SH06)

Tracks: 11. Radiotherapy

13. Palliative Care/Ethics

15. Regional Aspects/Health Policy/Public Health

Room: Hall C7

Chairs: Peter Berzinec, Slovakia & Herbert Watzke, Austria

- **Radiotherapy:**
TBD
- **Palliative Care/Ethics:**
Corey Langer, USA
- **Regional Aspects/Education:**
Prasanta R. Mohapatra, India

07:30 - 08:30: Special Workshop (WS09): Tobacco Free Portfolios

- **Learn How to Change the World for the Better - One Pension Fund at a Time!**
Bronwyn King, Australia

Room: Strauss 2

Overview: This workshop will provide a practical overview regarding how to effectively advocate for tobacco-free investment within your own country.

Who should attend?

- Leaders of international cancer agencies/organisations
- Any interested parties who might consider supporting a Tobacco Free Portfolios Regional Director or allocating this task to a staff member within the organization
- Motivated individuals who would like to contribute to the work

What will you learn? The Tobacco Free Portfolios team will cover:

- The case for tobacco-free investment: prospective investment risks including regulatory changes, litigation, human rights abuses and why tobacco as a unique consideration.
- Engaging the finance sector by understanding their priorities and concerns and learning to speak their language.
- Overview of financial investment in tobacco: from indices to collective investment vehicles.

- Becoming confident in answering the common questions posed by investors, finance leaders and government officials.

07:30 - 08:30: Meet the Expert (MTE21) (Ticketed Session: €35,00)

Track: Biology/Pathology

Room: Schubert 1

- **Next Generation Sequencing**
Ignacio Wistuba, USA & Xuefei Li, China

07:30 - 08:30: Meet the Expert (MTE22) (Ticketed Session: €35,00)

Track: Radiology/Staging/Screening

Room: Schubert 2

- **Perspectives in Lung Cancer Imaging**
Thomas Henzler, Germany & Georgios Karanikas, Austria

07:30 - 08:30: Meet the Expert (MTE23) (Ticketed Session: €35,00)

Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy

Room: Schubert 3

- **Biomarker Characterization: Challenges and Perspectives**
Rafael Rosell, Spain & Leonhard Müllauer, Austria

07:30 - 08:30: Meet the Expert (MTE24) (Ticketed Session: €35,00)

Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy

Room: Schubert 4

- **Immunohistochemical Assessment of Biomarkers for Immune Checkpoint Inhibitors**
Vera Capelozzi, Brazil

07:30 - 08:30: Meet the Expert (MTE25) (Ticketed Session: €35,00)

Track: SCLC/Neuroendocrine Tumors | Radiotherapy

Room: Schubert 5

- **Radiotherapy in Small Cell Lung Cancer**
Cecile Le Pechoux, France & Andrew Turrisi, USA

07:30 - 08:30: Meet the Expert (MTE26) (Ticketed Session: €35,00)

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: Schubert 6

- **EGFR Targeted Therapies: Lessons Learned**
Shun Lu, China & Federico Cappuzzo, Italy

07:30 - 08:30: Meet the Expert (MTE27) (Ticketed Session: €35,00)

Track: Chemotherapy/Targeted Therapy/Immunotherapy

Room: Lehar 1-2

- **Treatment of Lung Cancer Patients with Poor Performance Status**
Rogério Lilenbaum, USA & Luboš Petruželka, Czech Republic

07:30 - 08:30: Meet the Expert (MTE28) (Ticketed Session: €35,00)

Track: Regional Aspects/Health Policy/Public Health | Chemotherapy/Targeted Therapy/Immunotherapy

Room: Lehar 3-4

- **Implementation of Precision Medicine in Routine Practice : The Latin American Experience**
Marileila Varella-Garcia, USA & Mercedes Liliana Dalurzo, Argentina

07:30 - 08:30: Meet the Expert (MTE29) (Ticketed Session: €35,00)

Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

Room: Stolz 1

- **Advances in Malignant Pleural Mesothelioma**
Paolo Boffetta, USA & Nico van Zandwijk, Australia

07:30 - 08:30: Meet the Expert (MTE30) (Ticketed Session: €35,00)

Track: Surgery

Room: Stolz 2

- **Non-intubated Thoracic Surgery**
Teodor Horvath, Czech Republic, Jin-Shing Chen, Taiwan & Ya-Jung Cheng, Taiwan.

08:35 - 09:40: Plenary Session (PL04a): Immune Checkpoint Inhibitors in Advanced NSCLC

Room: Hall D (Plenary Hall)

Chairs: TBD & TBD

- 08:45 - **PL04a.01: Health-Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD-L1 TPS \geq 50%: Data from KEYNOTE-024**
Julie Brahmer, USA
- 08:55 - **PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses**
Shirish Gadgeel, USA
- 09:05 - **PL04a.03: Durvalumab in \geq 3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study**
Marina Garassino, Italy
- 09:15 - **PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC**
Julien Adam, France
- 09:25 - **PL04a.05: Discussant:**
Michael Boyer, Australia

09:45 - 10:15: Plenary Keynote Lecture (PL04b)

Chairs: Fred Hirsch, USA & Robert Pirker, Austria

- 09:45 - **PL04b.01: The Role of Doctors in a Globalized World**
Alfred Gusenbauer, Former Federal Chancellor of the Republic of Austria

10:20 - 11:00: Poster Session

Room: Hall B (Poster Area)

10:30: Press Conference (PR04)

Room: Schubert 1

11:00 - 12:30: Educational Session (ED11): Advanced NSCLC: State-of-the-Art Treatment

Track: Advanced NSCLC | Chemotherapy/Targeted Therapy/Immunotherapy

Room: C8

Chairs: Christian Manegold, Germany & Caicun Zhou, China

- 11:00 - **Systemic Therapy for Advanced Oncogene-Driven NSCLC**
David Gandara, USA
- 11:25 - **Systemic Therapy for Advanced Non-Oncogene-Driven NSCLC**

Giorgio Scagliotti, Italy

- 11:50 - **Management of Oligo-Metastatic NSCLC**
Jaroslaw Kuzdzal, Poland
- 12:10 - **Palliative Radiotherapy of Advanced NSCLC**
Karin Dieckmann, Austria

11:00 - 12:30: Educational Session (ED12): Regional Tobacco Control Policies: Advances & Challenges

Track: Epidemiology/Tobacco Control and Cessation/Prevention

Room: C7

Chairs: Zariah Zain, Malaysia & Florin Mihaltan, Romania

- 11:00 - **Tobacco Control Policies in Eastern Europe**
Gábor Kovács, Hungary
- 11:15 - **Tobacco Control: The Turkish Experience**
Nazmi Bilir, Turkey
- 11:30 - **Tobacco Control: The Indian Experience**
Surendra Shastri, India
- 11:45 - **Tobacco Control Policies in China**
Xiuyi Zhi, China
- 12:00 - **Tobacco Control Policies in Japan**
Tomotaka Sobue, Japan
- 12:15 - **Tobacco Control Policies in Latin America**
Nise Yamaguchi, Brazil

11:00 - 12:30: Educational Session (ED13): Treatment of Malignant Pleural Mesothelioma

Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

Room: C1

Chairs: Hedy Kindler, USA & Nico van Zandwijk, Australia

- 11:00 - **Biomarkers in Malignant Pleural Mesothelioma**
Harvey Pass, USA
- 11:15 - **Tissue-Based Biomarkers**
Glen Reid, Australia
- 11:30 - **Surgery with Adjuvant or Induction Radiotherapy**
Marc de Perrot, Canada
- 11:45 - **Systemic Induction Therapy of Malignant Pleural Mesothelioma**
Paul Baas, The Netherlands
- 12:00 - **Systemic Therapy of Inoperable Malignant Pleural Mesothelioma**
Arnaud Scherpereel, France
- 12:15 - **Mesothelioma in a Setting of Germline BAP1 Mutations**
Michele Carbone, USA

11:00 - 12:30: Science Session (SC24): Management of Indeterminate Pulmonary Nodules

Track: Pulmonology

Room: C2

Chairs: Nevena Secen, Serbia & Oleg Pikin, Russia

- 11:00 - **Risk Assessment in the Management of Pulmonary Nodules**
Satoshi Shiono, Japan
- 11:20 - **Radiological Techniques for the Evaluation of Pulmonary Nodules**

Reginald Munden, USA

- 11:35 - **The Role of the Pulmonologist in the Management of Pulmonary Nodules**
Philippe Lambin, The Netherlands
- 11:50 - **The Role of the Pathologist in the Management of Indeterminate Pulmonary Nodules**
Keith Kerr, UK
- 12:10 - **Indication and Techniques of Surgery**
Ugo Pastorino, Italy

11:00 - 12:30: Science Session (SC25): The Role of Surgeons in Multimodality Clinical Trials

Track: Surgery

Room: Strauss 2

Chairs: Norihiko Ikeda, Japan & TBD

- 11:00 - **Trial Design for Multimodality Treatment of NSCLC**
David Jones, USA
- 11:20 - **Quality of Resection in Induction and Adjuvant Clinical Trials**
Eric Vallieres, USA
- 11:40 - **Quality of Centers and Patient Inclusion**
John Edwards, UK
- 12:00 - **The Importance of Cooperation: The Essen Experience**
Wilfried Eberhardt, Germany
- 12:20 - **Q&A**

11:00 - 12:30: Science Session (SC26): Angiogenesis Inhibition: Advances & Perspectives

Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy

Room: Lehar 3-4

Chairs: Takashi Seto, Japan & Wolfgang Hilbe, Austria

- 11:00 - **Biology of Angiogenesis**
John Heymach, USA
- 11:20 - **Angiogenesis Inhibition in Lung Cancer: Recent Advances and Perspectives**
Michael Boyer, Australia
- 11:40 - **Predictive Biomarkers for Angiogenesis Inhibitors: An Update**
Martin Reck, Germany
- 12:00 - **Novel Imaging Technique**
Stefan Schönberg, Germany
- 12:20 - **Q&A**

11:00 - 12:30: Science Session (SC27): P53 and KRAS Mutations in NSCLC

Track: Biology/Pathology | Chemotherapy/Targeted Therapy/Immunotherapy

Room: Strauss 3

Chairs: Filippo de Marinis, Italy & Hideo Kunitoh, Japan

- 11:00 - **The Role of p53 in Lung Cancer**
Pierre Hainaut, France
- 11:20 - **Biology of KRAS Mutations**
József Tímár, Hungary
- 11:40 - **Transforming KRAS into a Clinically Relevant Biomarker**
Kenneth O'Byrne, Australia
- 12:00 - **KRAS-Directed Drug Therapy in Advanced NSCLC**
Pasi Jänne, USA

- 12:20 - Q&A

11:00 - 12:30: Science Session (SC28): Novel Clinical Trial Designs

Track: Trial Design/Statistics

Room: Lehar 1-2

Chairs: Stefan Michiels, France & Lothar Pilz, Germany

- 11:00 - **Phase I Trials of Targeted Therapies**
Alex Adjei, USA
- 11:20 - **Umbrella and Basket Designs**
Daniel Shao-Weng Tan, Singapore
- 11:40 - **Biomarker “Test and Validation” Designs**
Mary Redman, USA
- 12:00 - **Adaptive Clinical Trial Designs**
Vassiliki Papadimitrakopoulou, USA
- 12:20 - Q&A

11:00 - 12:30: Science Session (SC29): Access, Value Assessments and Affordability of Novel Therapies

Track: Chemotherapy/Targeted Therapy/Immunotherapy | Patient Support and Advocacy Groups

Room: Strauss 1

Chairs: Maciej Krzakowski, Poland & Eduardo Richardet, Argentina

- 11:00 - **Affordability of Novel Therapies: A Global Challenge**
Richard Sullivan, UK
- 11:20 - **Value-Based Assessments in Lung Cancer Therapy: The North American Perspective**
Ronan Kelly, USA
- 11:40 - **Value-based Assessments in Lung Cancer Therapy: The ESMO Perspective**
Nathan Cherny, Israel
- 12:00 - **Solutions for Low-Income Countries**
Gilberto Lopes, Brazil
- 12:15 - **The Thai Experience to overcome High Cost Drug in Cancer**
Sumitra Thongprasert, Thailand

11:00 - 12:30: Concurrent Abstract Sessions

11:00 - 12:30: Oral Session (OA18): New Insights in the Treatment of Thymic Malignancies

Room: Schubert 2

Chairs: Nicolas Girard, France & TBD

- 11:00 - **OA18.01: Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort**
Clémence Basse, France
- 11:10 - **OA18.02: Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma**
Arun Rajan, USA
- 11:20 - **OA18.03: Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)**
Arun Rajan, USA
- 11:30 - **OA18.04: Discussant:**
Andreas Rimner, USA

- 11:45 - **OA18.05: FDG-PET in Thymic Epithelial Tumors: An Evaluation of Only Resected Tumors**
Kazuo Nakagawa, Japan
- 11:55 - **OA18.06: Treatment, Outcome and Prognostic Factors of Patients with Thymic Epithelial Tumors at First Recurrence**
Rohit Lal, UK
- 12:05 - **OA18.07: Quality of Resection and Outcome in Stage III TETs: The French RYTHMIC Network Experience**
Nicolas Girard, France
- 12:15 - **OA18.08: Discussant:**
Enrico Ruffini, Italy

11:00 - 12:30: Oral Session (OA19): Translational Research in Early Stage NSCLC

Room: Schubert 3

Chairs: Gerwin Heller, Austria & Glenwood Goss, Canada

- 11:00 - **OA19.01: A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium**
Raphael Bueno, USA
- 11:10 - **OA19.02: Sex Differences Are Detected in the Profile of Tumor Associated Inflammatory Cells (TAICs) Are Lung Adenocarcinoma**
Carmen Behrens, USA
- 11:20 - **OA19.03: Identify Lung Adenocarcinoma in Situ among Pulmonary Micro-Nodules through Blood Gene Expression Profiles**
Baohui Han, China
- 11:30 - **OA19.04: Discussant:**
Charles Rudin, USA
- 11:45 - **OA19.05: High Oncofetal Chondroitin Sulfate Expression is an Independent Prognostic Factor of Poor Survival in Early-Stage NSCLC**
Zoltan Lohinai, Hungary
- 11:55 - **OA19.06: Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer**
Gavitt Woodard, USA
- 12:05 - **OA19.07: Difference of Postoperative Survival Due to the Type of EGFR Gene Mutation in Surgically Resected Lung Adenocarcinomas**
Kazuki Hayasaka, Japan
- 12:15 - **OA19.08: Discussant:**
Ken Andre Olausson, France

11:00 - 12:30: Oral Session (OA20): Immunotherapy and Markers

Room: Stolz 2

Chairs: Martin Früh, Switzerland & TBD

- 11:00 - **OA20.01: Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients**
Marcin Kowanetz, USA
- 11:10 - **OA20.02: Neoantigen Targeting in NSCLC Patients with Complete Response to Anti-PD-1 Immunotherapy**
Kellie Smith, USA
- 11:20 - **OA20.03: Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy**

- Zachary Tano, USA
- 11:30 - **OA20.04: Discussant:**
TBD
- 11:45 - **OA20.05: The Influence of Neoadjuvant Chemotherapy, on Immune Response Profile in Non-Small Cell Lung Carcinomas**
Jaime Rodriguez-Canales, USA
- 11:55 - **OA20.06: Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer - The ICON Project**
Boris Sepesi, USA
- 12:05 - **OA20.07: HHLA2, a New Immune Checkpoint Member of the B7 Family, is Widely Expressed in Human Lung Cancer and Associated with Mutational Status**
Haiying Cheng, USA
- 12:15 - **OA20.08: Discussant:**
Helmut Popper, Austria

11:00 - 12:30: Oral Session (OA21): Palliative and Supportive Care for Lung Cancer Patients

Room: Schubert 5

Chairs: Carlos Silva, Argentina & Herbert Watzke, Austria

- 11:00 - **OA21.01: Pooled Analysis of the Incidence and Risk of Treatment-Related Pneumonitis with Anti-PD-1/PD-L1 Therapies in Cancer Patients**
Shaodong Hong, China
- 11:10 - **OA21.02: ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism**
Alona Zer, Israel
- 11:20 - **OA21.03: Unmet Needs in Physical and Emotional Side Effects during Lung Cancer Treatment and Survivorship**
Jennifer King, USA
- 11:30 - **OA21.04: Discussant:** Navneet Singh, India
- 11:45 - **OA21.05: Wet M1a Non-Small Cell Lung Cancer: Is It Possible to Predict Recurrence of Pleural Effusion?**
Riad Younes, Brazil
- 11:55 - **OA21.06: Turning Best Supportive Care into Active Care. A Service Development for Patients with Advanced Lung Cancer in NHS Fife, Scotland**
Joanna Bowden, UK
- 12:05 - **OA21.07: Discussant:**
Eva Masel, Austria
- 12:20 - **Q & A**

12:45 - 14:15: Industry Supported Symposia: ISS Immuno-Oncology: A Renaissance in the Treatment of NSCLC - Merck Sharp & Dohme Corp.

Room: Lehar 3-4

Chair: David Carbone, USA

- 12:45 - **Welcome and Opening Remarks**
David Carbone, USA
- 12:50 - **Anti-PD-1 Experience in NSCLC**
Naiyer Rizvi, USA
- 13:10 - **The Value of PD-L1 Expression in NSCLC**
Keith Kerr, UK
- 13:25 - **Patient Management (Example Case)**

Benjamin Besse, France

- 13:40 - **NSCLC Landscape: Future Directions**
David Carbone, USA
- 13:55 - **Panel Discussion**
- 14:10 - **Closing Remarks**
David Carbone, USA

14:15 - 15:45: Concurrent Abstract Sessions

14:15 - 15:45: Oral Session (OA22): Novel Trials and Biomarkers in MPM

Room: Strauss 3

Chairs: Harvey Pass, USA & Nico van Zandwijk, Australia

- 14:15 - **OA22.01: STELLAR - Interim Results of a Phase 2 Trial of TTFIELDS with Chemotherapy for First Line Treatment of Malignant Mesothelioma**
Giovanni Ceresoli, Italy
- 14:25 - **OA22.02: Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial**
Federica Grosso, Italy
- 14:35 - **OA22.03: HMGB1, a Target for Mesothelioma Therapy and a Biomarker to Detect Asbestos Exposure and to Identify Mesothelioma Patients**
Haining Yang, USA
- 14:45 - **OA22.04: Discussant:**
Christian Diego Rolfo, Belgium
- 15:00 - **OA22.05: Breath Analysis by Gas Chromatography-Mass Spectrometry Can Be Used to Screen for Pleural Mesothelioma**
Kevin Lamote, Belgium
- 15:10 - **OA22.06: Refinement of the Prognostic miR-Score for Use in Diagnostic Specimens from Chemo-Naïve Malignant Pleural Mesothelioma Patients**
Michaela Kirschner, Switzerland
- 15:20 - **OA22.07: Correlation of CT Scan Based Tumor Volume Measurement to Actual Resected Tumor Volume - A New T-Factor?**
Isabelle Opitz, Switzerland
- 15:30 - **OA22.08: Discussant:**
Viktoria Laszlo, Austria

14:15 - 15:45: Oral Session (OA23): EGFR Targeted Therapies in Advanced NSCLC

Room: Stolz 2

Chairs: Odd Terje Brustugun, Norway & Shun Lu, China

- 14:15 - **OA23.01: Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First-Line Treatment of Advanced NSCLC: A Meta-Analysis**
Gilberto Lopes, Brazil
- 14:25 - **OA23.02: Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR-Expressing Tumors in SQUIRE, a Phase 3 Study**
Tudor Ciuleanu, Romania
- 14:35 - **OA23.03: Second-Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long-Term Responders in the Phase III LUX-Lung 8 Trial**
Glenwood Goss, Canada
- 14:45 - **OA23.04: Discussant:**
Martin Sebastian, Germany

- 15:00 - **OA23.05: First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7**
Keunchil Park, South Korea
- 15:10 - **OA23.06: Overall Survival (OS) of EGFR Mutation Positive Non-Small Cell Lung Cancer Patients: Real-World Treatment Patterns of 1,660 Japanese Patients**
Kazushi Yoshida, Japan
- 15:20 - **OA23.07: Analysis of Outcomes in US IRESSA Clinical Access Program (ICAP) Patients on Gefitinib for More Than 10 Years**
Fred R. Hirsch, USA
- 15:30 - **OA23.08: Discussant:**
Melissa Johnson, USA

14:15 - 15:45: Oral Session (OA24): Radiotherapy of Lung Cancer: Recent Developments

Room: Stolz 1

Chairs: Karin Dieckmann, Austria & TBD

- 14:15 - **OA24.01: Radiotherapy Quality Assurance of Concurrent Chemoradiotherapy in PROCLAIM Phase III Trial**
Anthony Brade, Canada
- 14:25 - **OA24.02: Locally Advanced Non-Small Cell Lung Cancer: RadioTherapy with Adaptive Strategy (LARTIA Trial)**
Sara Ramella, Italy
- 14:35 - **OA24.03: Cardiac Toxicity after Radiation for Stage III NSCLC: Pooled Analysis of Dose-Escalation Trials Delivering 70-90 Gy**
Kyle Wang, USA
- 14:45 - **OA24.04: Discussant:**
TBD
- 15:00 - **OA24.05: The Nordic HILUS-Trial - First Report of a Phase II Trial of SBRT of Centrally Located Lung Tumors**
Karin Lindberg, Sweden
- 15:10 - **OA24.06: Histologic Subtype of Early-Stage Lung Adenocarcinoma is a Predictor of Failure Patterns after Stereotactic Body Radiation Therapy**
Abraham Wu, USA
- 15:20 - **OA24.07: The Impact of Population Heterogeneity on the Efficacy of SBRT to the Lung**
Mohamed Abazeed, USA
- 15:30 - **OA24.08: Discussant:**
TBD

14:15 - 15:45: Mini Oral Session (MA15): Immunotherapy Prediction

Room: Schubert 1

Chairs: Maya Gottfried, Israel & TBD

- 14:15 - **MA15.01: Immunogram for Cancer-Immunity Cycle towards Personalized Immunotherapy of Lung Cancer**
Takahiro Karasaki, Japan
- 14:21 - **MA15.02: Non-Synonymous Mutation Burden in Lung Carcinoma is Associated with Durable Clinical Response to Immune Checkpoint Blockade**
Navin Mahadevan, USA
- 14:27 - **MA15.03: The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC**

- Weijing Cai, China
- 14:33 - **MA15.04: Discussant:**
Jürgen Fischer, Germany
 - 14:45 - **MA15.05: PD-L1 Immunohistochemistry as Biomarker in Non-Small Cell Lung Cancer (NSCLC)**
Dagmar Krenbek, Austria
 - 14:51 - **MA15.06: Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD-1 Axis Therapy in Non-Small Cell Lung Cancer (NSCLC)**
Kurt Schalper, USA
 - 14:57 - **MA15.07: Molecular Determinants of Lack of Tumor Immune Infiltration in NSCLC**
Thomas Hensing, USA
 - 14:03 - **MA15.08: Discussant:**
TBD
 - 15:15 - **MA15.09: Response to the Treatment Immediately before Nivolumab Monotherapy May Predict Clinical Response to Nivolumab**
Haruki Kobayashi, Japan
 - 15:21 - **MA15.10: Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma**
Zhong-Yi Dong, China
 - 15:27 - **MA15.11: Acquired Resistance Mechanisms to EGFR Kinase Inhibitors Alter PD-L1 Expression Status in Lung Cancer**
Kenichi Suda, USA
 - 15:33 - **MA15.12: Discussant:**
Martin Früh, Switzerland

14:15 - 15:45: Mini Oral Session (MA16): Novel Strategies in Targeted Therapy

Room: Strauss 2

Chairs: Gunta Purkalne, Latvia & Joachim von Pawel, Germany

- 14:15 - **MA16.01: Targeted Gene Therapy for Tobacco Carcinogen-Induced Lung Cancer**
Nomundelger Gankhuyag, South Korea
- 14:21 - **MA16.02: Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas**
Katerina Politi, USA
- 14:27 - **MA16.03: Global RET Registry (GLORY): Activity of RET-Directed Targeted Therapies in RET-Rearranged Lung Cancers**
Oliver Gautschi, Switzerland
- 14:33 - **MA16.04: Discussant:**
Myung-Ju Ahn, South Korea
- 14:45 - **MA16.05: For EGFR Mutant Non-Small Cell Lung Cancer, Treatment Sequence Matters? - Ho Jung An, South Korea**
- 14:51 - **MA16.06: Phase I/II Study of AC0010, Mutant-Selective EGFR Inhibitor, in Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation**
Yi Long Wu, China
- 14:57 - **MA16.07: Drug Repurposing to Overcome De Novo Resistance of Non-Traditional EGFR Mutations**
Jacquelyne Robichaux, USA
- 15:03 - **MA16.08: Discussant:**
Thanyanan Reungwetwattana, Thailand

- 15:15 - **MA16.09: Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14- Altered Advanced Non-Small Cell Lung Cancer**
Alex Drilon, USA
- 15:21 - **MA16.10: Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates**
Vassiliki Papadimitrakopoulou, USA
- 15:27 - **MA16.11: CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC: Pooled Data from Two Phase II Trials**
Glenwood Goss, Canada
- 15:33 - **MA16.12: Discussant:**
Edgardo Santos, USA

14:15 - 15:45: Mini Oral Session (MA17): Genetic Drivers

Room: Lehar 1-2

Chairs: Miyako Satouchi, Japan & George Simon, USA

- 14:15 - **MA17.01: Microarray Identification of Genetic Drivers of Brain Metastasis in Lung Adenocarcinoma**
Gavitt Woodard, USA
- 14:21 - **MA17.02: Genome-Wide Copy Number and Mutational Analysis in Longitudinal Biopsies of Matched Primary and Metastatic Pulmonary Adenocarcinomas**
Thomas Lorber, Switzerland
- 14:27 - **MA17.03: Identifying Genomic Alteration and Inter-Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and ctDNA**
Kezhong Chen, China
- 14:33 - **MA17.04: Discussant:**
József Tímár, Hungary
- 14:45 - **MA17.05: Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas**
Hao-ran Zhai, China
- 14:51 - **MA17.06: Landscape of Somatic Mutations Involving Lung Cancer Associated Genes in Non-Small Cell Lung Cancer (NSCLC) Patient-Derived Xenografts** - Vibha Raghavan, Canada
- 14:57 - **MA17.07: Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer**
Maximilian Diehn, USA
- 15:03 - **MA17.08: Discussant:**
Leonhard Müllauer, Austria
- 15:15 - **MA17.09: Premature Fibroblast Senescence in Large Cell Carcinoma Provides Enhanced Growth and Invasive Advantages to Cancer Cells in Culture and in vivo**
Marta Gabasa, Spain
- 15:21 - **MA17.10: YES1 Kinase is a New Therapeutic Target in Non-small Cell Lung Cancer**
Luis Montuenga, Spain
- 15:27 - **MA17.11: Knockdown of Akt2 Suppresses Tumorigenesis and Raf1 Overexpression Offsets This Effect in Non-Small Cell Lung Cancer**
Shuang Zhao, China
- 15:33 - **MA17.12: Discussant:**
Sanja Dacic, USA

14:30 - 15:45: Educational Session (ED14): Small Cell Lung Cancer

Track: SCLC/Neuroendocrine Tumors

Room: C2

Chairs: Jens Benn Sørensen, Denmark & Sabine Zöchbauer-Müller, Austria

- 14:30 - **Chemotherapy of Small Cell Lung Cancer**
Primo Lara, USA
- 14:45 - **Thoracic Radiotherapy of SCLC**
Berend Slotman, The Netherlands
- 15:00 - **Update on Prophylactic Cranial Irradiation in SCLC**
Takashi Seto, Japan
- 15:15 - **Is there a Role for Surgery in SCLC?**
Georgios Stamatis, Germany
- 15:30 - **Immunotherapy of Small Cell Lung Cancer**
Nevin Murray, Canada

14:30 - 15:45: Educational Session (ED15): Thymic Malignancies: Update on Treatment

Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

Room: C1

Chairs: Heather Wakelee, USA & Paul Van Schil, Belgium

- 14:30 - **Biology of Thymic Epithelial Tumors**
Giuseppe Giaccone, USA
- 14:50 - **Chemotherapy and Targeted Therapies of Thymic Malignancies**
Nicolas Girard, France
- 15:10 - **Surgery of Thymic Malignancies**
Meinoshin Okumura, Japan
- 15:30 - **Radiation of Thymic Malignancies**
Andreas Rimner, USA

14:30 - 15:45: Science Session (SC30): Novel Approaches and Regulation in Surgical Education

Track: Surgery

Room: C8

Chairs: Dominique Grunenwald, France & Young Tae Kim, South Korea

- 14:30 - **Simulation-Based Thoracic Surgery Training**
TBD
- 14:50 - **Animal Models for Training of Thoracic Surgeons**
TBD
- 15:10 - **E-Learning in Thoracic Oncology**
Jalal Assouad, France
- 15:30 - **Impact of Working Time Directives on Thoracic Surgical Training: The North-American Experience**
Claude Deschamps, USA

14:30 - 15:45: Science Session (SC31): Together Against Lung Cancer - A Strategy for Success in the 21st Century

Track: Scientific Co-Operation/Research Groups | Regional Aspects/Health Policy/Public Health

Room: C7

Chairs: Michael Boyer, Australia & Pieter Postmus, UK

- 14:30 - **The Role of Scientific Organizations**
Paul Bunn, Jr., USA
- 14:50 - **The Role of Patient Advocacy Groups**

Bonnie Addario, USA

- 15:10 - **The Role of Medical Journals**
David Collingridge, UK
- 15:30 - **The Possibilities of Print & Social Media**
Wolfgang Wagner, Austria

14:30 - 15:45: Nurses Session (NU05): Survivorship

Track: Nurses

Room: Schubert 5

Chairs: Beth Ivimey, Australia & Maria Guerin, UK

- 14:30 - **Use of Inspiratory Muscle Training in Managing Dyspnoea in Lung Cancer Patients**
Andreas Charalambous, Cyprus
- 14:50 - **Comprehensive Long-Term Care of Lung Cancer Patients: Development of a Novel Thoracic Survivorship Program**
James Huang, USA
- 15:10 - **What can we Learn from Other Tumor Sites About Survivorship**
Natalie Doyle, UK
- 15:30 - **Q&A**

14:30 - 15:45: Young Investigator Session (YI02): Basics of Radio-Oncology

Track: Radiotherapy

Room: Strauss 1

Chairs: Corinne Faivre-Finn, UK & Rolf Lewensohn, Sweden

- 14:30 - **PET-CT and MRI for Radiotherapy Planning of Lung Cancer**
Ursula Nestle, Germany
- 14:50 - **Modern Treatment Techniques in Lung Cancer: The Advantages of Conformal Radiotherapy, IMRT and Proton Therapy**
Satoshi Ishikura, Japan
- 15:10 - **Dose Limitations for Radiotherapy of Lung Cancer**
Antonio Juretic, Croatia
- 15:30 - **Career Development in Radiation Oncology**
Laurie Gaspar, USA

14:30 - 15:45: Poster Session with Presenters Present (P3)

Room: Hall B (Poster Area)

- [Click here for the 17th IASLC WCLC Poster Program >>](#)

16:00 - 18:00: Closing Plenary Session (PL05): A Life in Thoracic Oncology - Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer

Room: Hall D (Plenary Hall)

Chairs: Paul Bunn, Jr., USA & Tony Mok, Hong Kong

- 16:00 - **PL05.01: Pathology**
Adi Gazdar, USA
- 16:15 - **PL05.02: Surgery**
Peter Goldstraw, UK
- 16:30 - **PL05.03: Radio-Oncology**
David Ball, Australia

- 16:45 - **PL05.04: Translational Lung Cancer Research**
Nagahiro Saijo, Japan
- 17:00 - **PL05.05: Chemotherapy**
Thierry Le Chevalier, France
- 17:15 - **PL05.06: Targeted Therapy**
Frances Shepherd, Canada
- 17:30 - **PL05.07: A Wise Man's Conclusion**
Lawrence Einhorn, USA
- 17:45 - **PL05.08: Welcome to Yokohama for WCLC 2017**
Hisao Asamura, Japan
- 17:55 - **PL05.09: Farewell**
Robert Pirker, Austria

19:00 - 22:00: WCLC 2016 Together Against Lung Cancer (Ticketed Event: €99,00)
The Hofburg